<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">103817</article-id><article-id pub-id-type="doi">10.7554/eLife.103817</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.103817.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>PPARγ mediated enhanced lipid biogenesis fuels <italic>Mycobacterium tuberculosis</italic> growth in a drug-tolerant hepatocyte environment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sarkar</surname><given-names>Binayak</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0009-3366-4851</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Jyotsna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yadav</surname><given-names>Mohit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Priya</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Raman Deep</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Shweta</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chandramouli</surname><given-names>Aakash</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mehdiratta</surname><given-names>Kritee</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Ashwani</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Kamat</surname><given-names>Siddhesh S</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ghorpade</surname><given-names>Devram S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mohanty</surname><given-names>Debasisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7578-2930</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gokhale</surname><given-names>Rajesh S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6597-2685</contrib-id><email>rsg@nii.ac.in</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04fhee747</institution-id><institution>Immunometabolism Laboratory, National Institute of Immunology</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03j4rrt43</institution-id><institution>Cellular Immunology Group, International Centre for Genetic Engineering and Biotechnology</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/055rjs771</institution-id><institution>CSIR-Institute of Microbial Technology</institution></institution-wrap><addr-line><named-content content-type="city">Chandigarh</named-content></addr-line><country>India</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028qa3n13</institution-id><institution>Indian Institute of Science Education and Research</institution></institution-wrap><addr-line><named-content content-type="city">Pune</named-content></addr-line><country>India</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05ef28661</institution-id><institution>Council of Scientific and Industrial Research–Institute of Genomics and Integrative Biology (CSIR-IGIB)</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053rcsq61</institution-id><institution>Academy of Scientific and Innovative Research (AcSIR)</institution></institution-wrap><addr-line><named-content content-type="city">Ghaziabad</named-content></addr-line><country>India</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Indian Institute of Science Education and Research, Pune, India</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>12</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP103817</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-10-21"><day>21</day><month>10</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-10-06"><day>06</day><month>10</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.02.02.578554"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-01-06"><day>06</day><month>01</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103817.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-09-05"><day>05</day><month>09</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103817.2"/></event></pub-history><permissions><copyright-statement>© 2025, Sarkar et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Sarkar et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-103817-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-103817-figures-v1.pdf"/><abstract><p><italic>Mycobacterium tuberculosis</italic> (Mtb) infection of the lungs, besides producing prolonged cough with mucus, also causes progressive fatigue and cachexia with debilitating loss of muscle mass. While anti-tuberculosis (TB) drug therapy is directed toward eliminating bacilli, the treatment regimen ignores the systemic pathogenic derailments that probably dictate TB-associated mortality and morbidity. Presently, it is not understood whether Mtb spreads to metabolic organs and brings about these impairments. Here, we show that Mtb creates a replication-conducive milieu of lipid droplets in hepatocytes by upregulating transcription factor PPARγ and scavenging lipids from the host cells. In hepatocytes, Mtb shields itself against the common anti-TB drugs by inducing drug-metabolizing enzymes. Infection of the hepatocytes in the in vivo aerosol mice model can be consistently observed post-week, 4 along with enhanced expression of PPARγ and drug-metabolizing enzymes. Moreover, histopathological analysis indeed shows the presence of Mtb in hepatocytes along with granuloma-like structures in human biopsied liver sections. Hepatotropism of Mtb during the chronic infectious cycle results in immuno-metabolic dysregulation that could magnify local and systemic pathogenicity, altering clinical presentations.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>Mycobacterium tuberculosis</italic></kwd><kwd>mouse</kwd><kwd>human</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028vaas30</institution-id><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Gokhale</surname><given-names>Rajesh S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ffdsr55</institution-id><institution>Science and Engineering Research Board</institution></institution-wrap></funding-source><award-id>SB/SJF/2021-22/01</award-id><principal-award-recipient><name><surname>Kamat</surname><given-names>Siddhesh S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0101xrq71</institution-id><institution>Department of Science and Technology Fund for Improvement of S&amp;T Infrastructure (DST-FIST)</institution></institution-wrap></funding-source><award-id>SR/FST/LSII-043/2016</award-id><principal-award-recipient><name><surname>Kamat</surname><given-names>Siddhesh S</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In vitro, ex vivo, and in vivo studies reveal that hepatocytes are significantly infected by <italic>Mycobacterium tuberculosis</italic> which rewires the host cell metabolism to upregulate the lipid biosynthetic pathways.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p><italic>Mycobacterium tuberculosis</italic> (Mtb), the causative agent of human tuberculosis, remains the leading infectious killer globally, with an estimated death of 1.3 million in 2022 (<xref ref-type="bibr" rid="bib61">World Health Organisation, 2023</xref>). Despite progressive work on designing new anti-TB therapeutics and implementing vaccination programs in TB-endemic countries, it has a high global case fatality rate and a poor treatment success rate, along with a rising number of drug-resistant infections (<xref ref-type="bibr" rid="bib52">Seung et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Husain et al., 2016</xref>). Emerging paradigms in infectious diseases advocate tackling pathogen-driven ailments as one-dimensional problems, where the entire emphasis is given to pathogen elimination. A holistic understanding of how the host systems respond to the infection, vaccination, and treatment is key to TB management programs (<xref ref-type="bibr" rid="bib22">Eckhardt et al., 2020</xref>). Recent widespread and severe physiological derangements associated with COVID-19 patients, even after the elimination of the virus, have brought back the focus on identifying novel strategies that are inclusive of modulating the host immune-metabolic axis (<xref ref-type="bibr" rid="bib16">Davis et al., 2023</xref>; <xref ref-type="bibr" rid="bib34">Lippi et al., 2023</xref>).</p><p>The clinical symptoms of pulmonary TB encompass localized manifestations like prolonged cough with mucus, pleuritic chest pain, hemoptysis, and lung damage. Besides, systemic outcomes like cachexia, progressive fatigue, oxidative stress, altered microbiota, and glucose intolerance result in organ-wide disruptions (<xref ref-type="bibr" rid="bib39">Luies and du Preez, 2020</xref>; <xref ref-type="bibr" rid="bib36">Loddenkemper et al., 2015</xref>). Pulmonary TB patients often suffer from progressive and debilitating loss of muscle mass and function, with severe weight loss, this TB-associated cachexia cannot be reversed by conventional nutritional support (<xref ref-type="bibr" rid="bib42">Morley et al., 2006</xref>; <xref ref-type="bibr" rid="bib12">Chang et al., 2013</xref>). Besides, numerous epidemiological studies indicate that hyperglycemia may occur during active tuberculosis, which can compromise insulin resistance and glucose tolerance, although the mechanisms are unclear (<xref ref-type="bibr" rid="bib39">Luies and du Preez, 2020</xref>; <xref ref-type="bibr" rid="bib8">Bisht et al., 2023</xref>; <xref ref-type="bibr" rid="bib43">Niazi and Kalra, 2012</xref>). Both the localized and systemic pathophysiology of TB infection indicate an alteration in the host immuno-metabolic axis. It is somewhat bewildering that the engagement of the liver during the Mtb infection cycle is not considered, despite its central role in balancing the immune and metabolic functions of the body (<xref ref-type="bibr" rid="bib30">Jensen-Cody and Potthoff, 2021</xref>). The crosstalk between the liver and lung has been largely overlooked in TB, even though acute phase proteins (APPs) are used as predictive biomarkers in pulmonary tuberculosis (<xref ref-type="bibr" rid="bib32">Kumar et al., 2021</xref>). A robust hepatic APR response in mice, mediated by key hepatocyte transcription factors, STAT3 and NF-κB/RelA, has been known to trigger pulmonary host defences for survival during pneumonia and sepsis (<xref ref-type="bibr" rid="bib46">Quinton et al., 2018</xref>). In TB, the active phase of the disease is associated with heightened expression of various genes that modulate flux in the lipid metabolic pathways (<xref ref-type="bibr" rid="bib54">Shim et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Park et al., 2021</xref>; <xref ref-type="bibr" rid="bib24">Gago et al., 2018</xref>).</p><p>The liver is involved in a wide variety of functions – synthesis of plasma proteins, secretion of various hepatokines, degradation of xenobiotic compounds, and storage of lipids, glucose, vitamins, and minerals (<xref ref-type="bibr" rid="bib58">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib3">Alper et al., 1969</xref>). De novo lipogenesis, secretion of acute phase proteins, hepatokine production, etc., are all directly or indirectly controlled by the hepatocytes, thereby communicating with almost all the organs of the body (<xref ref-type="bibr" rid="bib58">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib65">Zhou et al., 2016</xref>). Moreover, the liver is actively involved in triacylglycerol synthesis and storage under the intricate regulation of various hormones like insulin, glucagon, and thyroid hormone (<xref ref-type="bibr" rid="bib64">Zhang et al., 2022</xref>). All these functions uniquely position the liver as the central regulator of lipid metabolism. To avert organ damage, the liver maintains tolerogenic properties rendering it an attractive target for various pathogenic microorganisms. Although several studies have indicated the role of both -Mtb virulence components and host factors (immune activation, nitric oxide, IFNγ, intracellular pH, and hypoxia) in the generation of Mtb drug tolerance, the role of liver, being the principal center for xenobiotic metabolism needs careful investigation (<xref ref-type="bibr" rid="bib15">Datta et al., 2024</xref>; <xref ref-type="bibr" rid="bib18">Deb et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Samuels et al., 2022</xref>; <xref ref-type="bibr" rid="bib50">Santucci et al., 2021</xref>). Liver is the hub of both phase I and phase II drug-modifying enzymes (DMEs). The levels as well as the activity of both types of DMEs play significant roles in determining the pharmacokinetics and efficacy of various drugs across multiple diseases, from infection to malignancy (<xref ref-type="bibr" rid="bib63">Wu and Lin, 2019</xref>).</p><p>In this study, we demonstrate the active involvement of the liver in a murine aerosol TB infection model during the chronic phase and establish hepatocytes as a new replicative niche for Mtb. Using a variety of in vivo, ex vivo, and in vitro techniques, we show how Mtb perturbs biological functions within hepatocytes remodeling intracellular growth, localization, and drug sensitivity. Cellular and mass spectrometric studies demonstrate Mtb infection-mediated enhanced fatty acid biogenesis and TAG biosynthesis in the hepatocytes regulated by PPARγ. We propose that infection of hepatocytes by Mtb during the chronic phase can contribute to significant changes in disease progression, TB treatment, and the development of infection-induced metabolic diseases.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Human miliary tuberculosis patients harbor Mtb in the liver</title><p>Mtb infects lungs, and other organs like lymph nodes, pleura, bones, and meninges. There are also isolated case reports of hepatic TB, without providing many pathophysiological consequences (<xref ref-type="bibr" rid="bib62">Wu et al., 2013</xref>; <xref ref-type="bibr" rid="bib57">Turhan et al., 2011</xref>). To gain further insights into the involvement of the liver in Mtb infections, we acquired human autopsied liver samples from individuals with miliary tuberculosis and analyzed them for the presence of Mtb bacilli (the details of the human samples have been included in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Hematoxylin and eosin (H and E) staining showed the presence of distinct immune cell infiltration and granuloma-like structures in the infected samples (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). We examined the liver specimens, with Mtb-specific Ziehl-Nielsen (Z-N) acid-fast and auramine O-rhodamine B stain (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). Both these stains showed distinct positive signals with characteristic rod-shaped bacilli that could be visualized by the acid-fast staining (as indicated by arrows) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We further corroborated our findings by performing fluorescence in situ hybridization (FISH) using Mtb-specific 16 s rRNA probes, where specific signals were observed (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The specific staining in FISH eliminates the possibility of non-tuberculous mycobacteria (NTMs) in the tissue specimen and confirms the presence of Mtb infection in the liver. Similar staining in the uninfected liver sections from other individuals did not show any signal (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). Although hepatic granuloma is the characteristic histological feature for both local and miliary forms of hepatic TB, the precise involvement of the different cells like Kupffer cells, hepatocytes, stellate cells, liver sinusoidal endothelial cells, hepatic stellate cells, and other cell types has not been studied in detail (<xref ref-type="bibr" rid="bib27">Hickey et al., 2015</xref>). Multiplex immunostaining with β-actin antibody and Mtb-specific Ag85B antibody shows the presence of Ag85B signals within the human hepatocytes, further confirming the presence of Mtb within hepatocytes (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>), indicated with yellow arrows. Hepatocytes are morphologically distinct, large polygonal cells (20–30 µm) with round nuclei, many of which are double-nucleated and mainly positioned at the center of the cytoplasm (<xref ref-type="bibr" rid="bib11">Celton-Morizur et al., 2010</xref>). The presence of Ag85B signals near the nucleus, as depicted in <xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>, further supports our assertion. Moreover, hepatic granulomas in the human samples showed localized clustering of the immune cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). The corresponding Ag85B staining in the uninfected liver biopsy samples did not show any signal (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Furthermore, to establish a correlation between liver Mtb load and Mtb burden at the primary infection site, the lung, we conducted H&amp;E staining and acid-fast staining on lung sections from the same individuals. H&amp;E staining revealed distinct granulomas, while acid-fast staining confirmed an elevated bacterial load, both indicative of a high degree of infection (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E and F</xref>). Using auramine O-rhodamine B, Ziehl-Nielsen acid-fast staining, and FISH, Mtb presence was detected in several lung specimens (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). These results indicate Mtb infection in the liver of human subjects and suggest the localization of Mtb within hepatocytes. These findings are quite intriguing considering very few studies have discussed the lung-liver crosstalk or the involvement of liver in pulmonary TB.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Presence of <italic>Mycobacterium tuberculosis</italic> (Mtb) in the liver of human miliary tuberculosis patients.</title><p>(<bold>A</bold>) Hematoxylin and eosin (H and E) staining of the human autopsied liver tissue sections showing the presence of granuloma-like structure in the Mtb-infected liver. (<bold>B</bold>) Acid-fast staining shows the presence of Mtb in the liver section of miliary tuberculosis (TB) patients (arrows point to the presence of Mtb in the enlarged image). (<bold>C–D</bold>) Auramine O-Rhodamine B (<bold>A–O</bold>) staining and fluorescence in situ hybridization (FISH) with Mtb-specific 16 s rRNA primer further confirms the presence of Mtb in human liver tissue sections. (<bold>E</bold>) Dual staining of β-actin (green) and Ag85B (red) using respective antibodies shows the presence of Mtb in hepatocytes of human biopsied liver sections. (<bold>F</bold>) Dual staining of β-actin (green) and Ag85B (red) using respective antibodies shows no distinct signal of Ag85B in the uninfected liver biopsied sample (control). The data is representative from six human patient samples.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Histopathological changes in the liver biopsy samples of miliary tuberculosis (TB) patients: (<bold>A and B</bold>) A-O staining and fluorescence in situ hybridization (FISH) in the liver biopsy of the uninfected (control) group shows no <italic>Mycobacterium tuberculosis</italic> (Mtb)-specific signals.</title><p>(<bold>C</bold>) Hematoxylin and eosin (H&amp;E) staining shows enhanced immune cell infiltration in the liver biopsy of the pulmonary TB patients compared to the uninfected control. (<bold>D</bold>) Dual staining of β-actin (green) and Ag85B (red) using respective antibodies shows the presence of Mtb in hepatocytes and other cells in liver biopsy sections (indicated by yellow arrows) (<bold>E</bold>) H&amp;E staining shows distinct granuloma in the lung section of pulmonary TB patient and (<bold>F</bold>) Acid-fast staining in the same lung section shows a high bacterial load (<bold>G</bold>) A-O staining in the same lung section further validates the presence of high Mtb load. Scale bars in A, B, and C are 50 μm and in D is 20 μm. and E and F are 150 μm. Data shown in this figure is representative of 5 patients with miliary TB.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Mtb infection of mice via the aerosol route leads to significant infection of the liver and primary hepatocytes</title><p>To investigate whether the liver harbours Mtb during mice aerosol infection, we infected C57BL/6 mice with 200 CFU of Mtb <italic>H37Rv</italic> and scored for the bacterial load in the conventional niche- the lung as well as in the liver. Mtb could be detected in the liver consistently across several experiments at 4 weeks post-infection and the bacterial load increased till week 10 (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Consistent with the Mtb burden, phalloidin and hematoxylin and eosin (H and E) staining of the infected liver at 8 weeks post-infection showed localized cellular aggregation forming ectopic granulomas forming a granuloma-like structure (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Further staining the liver sections with CD45.2 antibody shows clustering of immune cells in Mtb-infected mice liver (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). To assess whether liver infection leads to deranged liver function in the aerosol model, we analyzed the levels of liver functional enzymes like albumin, aspartate transaminase (AST), alanine transaminase (ALT), and gamma-glutamyl transpeptidase (GGT) in the sera. Till week 10 post-infection, sera levels of these markers showed significant alterations as the infection progressed, especially in the levels of AST with changes also in the levels of albumin and GGT (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Since hepatocytes, the principal parenchymal cells of the liver constitute 70–80 % of the liver by weight, we hypothesized whether hepatocytes could harbour Mtb in the murine model of infection. To this end, we isolated primary hepatocytes from the Mtb-infected mice at different time points post-infection. The purity of the isolated hepatocytes was validated by multiple methods-morphologically hepatocytes can be identified by their distinct hexagonal architecture, round nucleus, some of which are binucleated, as observed in Alexa fluor phalloidin 488 and DAPI-stained hepatocytes (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Flow cytometry staining with antibody against hepatocyte-specific marker asialoglycoprotein receptor 1 (ASGR1) protein, confirmed that almost 100 % of the isolated cells are primary hepatocytes as seen in (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). It was further validated by confocal microscopy as all the cultured cells specifically stained for ASGR1 protein, although with variable levels of expression (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). After thorough confirmation of the identity and the purity of the hepatocytes, the cells were lysed and plated. Like the whole liver CFU, Mtb-infected primary hepatocytes (PHCs) at 4 weeks post-infection with substantial bacterial load at week 6 and week 8 (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Staining with antibody for Mtb-specific Ag85B protein in both the infected tissue sections and cultured hepatocytes isolated from the in vivo infected mice revealed the presence of Mtb within hepatocytes (<xref ref-type="fig" rid="fig2">Figure 2D and I</xref>). To further strengthen our data, we co-stained the isolated primary hepatocytes from the Mtb-infected mice with anti-albumin antibody (albumin is a robust and widely used hepatocyte marker) and Ag85B. As depicted in (<xref ref-type="fig" rid="fig2">Figure 2J</xref>)<bold>,</bold> distinct Ag85B signals can be observed in the albumin-rich hepatocytes. Even at a low CFU of 50, Mtb load was observed in the liver at week 6 and 8 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). Besides the aerosol route, infection intraperitoneally also led to hepatocyte infection, also led to hepatocyte infection as early as day 10 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Further, to prove the spread of Mtb to the liver in other model organisms, we infected guinea pigs with 200 CFU of Mtb and analyzed the bacterial load in the lung, liver, and spleen at week 4 and week 8 post-infection (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). At both the time points, we could observe robust liver infection with granulomatous structure in the liver, proving that the dissemination of Mtb to the liver occurs across multiple model animals (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Involvement of the liver and hepatocytes in a mouse aerosol model of <italic>Mycobacterium tuberculosis</italic> (Mtb) infection.</title><p>(<bold>A</bold>) Schematic denoting the flow of experimental set up of studying the liver at tissue level and cellular level (generated using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/z1d3l89">Biorender.com</ext-link>). (<bold>B</bold>) C57BL/6 mice were infected with 200 colony-forming units (CFU) of H37Rv through the aerosol route and the bacterial burden of the lung and liver was enumerated at different time points post-infection in lung and spleen. n=5 mice/group and the data is representative from three independent biological experiments (<bold>C</bold>) Alexa Fluor 488 Phalloidin and DAPI staining of uninfected and infected lungs at 8 weeks post-infection. Images were taken in 40 X magnification as mentioned (scale bar is 20 μm). (<bold>D</bold>) Immunofluorescence staining of Alexa Fluor 488 Phalloidin, DAPI, and Ag85B in the infected mice liver at 8 weeks post-infection shows the presence of Ag85B signals within hepatocytes (magnified image) (scale bar is 20 μm). (<bold>E</bold>) Isolated primary hepatocytes stained with phalloidin green and DAPI show the typical polygonal shape with binucleated morphology. (<bold>F</bold>) Anti-asialoglycoprotein receptor (ASGR1) antibody staining specifically stains primary hepatocytes isolated from infected mice, as validated by the contour plot in flow cytometry. (<bold>G</bold>) Antiasialoglycoprotein receptor (ASGR1) antibody staining specifically stains primary hepatocytes isolated from mice, as visualized through confocal microscopy. (<bold>H</bold>) Primary hepatocytes were isolated from the infected mice, lysed and CFU enumeration was done at the mentioned time points. (<bold>I</bold>) Ag85B staining of cultured primary hepatocytes, isolated from mice at 8 weeks post-Mtb infection. (Scale bar is 20 μm). (<bold>J</bold>) Dual immunostaining of Ag85B (red) and albumin (green) shows distinct signals of Mtb within the isolated hepatocytes from infected mice at 8 weeks post-infection. The figures show representative data from four independent biological experiments.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Data used for plotting the graph in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Data used for plotting the graph in <xref ref-type="fig" rid="fig2">Figure 2H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig2-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Histopathological changes in the murine liver post <italic>Mycobacterium tuberculosis</italic> (Mtb) infection.</title><p>(<bold>A</bold>) 10<sup>5</sup> number of H37Rv were administered intraperitoneally (IP) and the bacterial burden was enumerated in primary hepatocytes that were isolated from the infected mice at the mentioned time points post-infection. (<bold>B</bold>) Analysis of the serum parameters of albumin, alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyl transpeptidase (GGT) in the uninfected and infected mice at the mentioned time points, mice were infected through the aerosol route with 200 colony-forming units (CFU). (<bold>C</bold>) Representative hematoxylin and eosin (H&amp;E)-stained liver sections show enhanced immune cell infiltration in Mtb-infected mice. (<bold>D</bold>) Multiplex immunostaining of infected mice liver with CD 45.2 and Ag85B indicates the presence of Ag85B-positive signals in CD 45.2 cells. Sample size (<bold>E</bold>) Bacterial load in the primary hepatocytes of mice infected with 50 CFU of H37Rv at 6- and 8 weeks post-infection. The figures show representative data from three independent biological experiments.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig2-figsupp1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig2-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Involvement of the liver in the guinea pig aerosol infection model.</title><p>(<bold>A</bold>) Guinea pigs were infected with 200 colony-forming units (CFU) of H37Rv through the aerosol route and the bacterial burden of the lungs, liver, and spleen was enumerated at different time points post-infection (<bold>B</bold>) Hematoxylin and eosin (H&amp;E) images of the lung and the liver at 4- and 8 weeks post-infection showing distinct granulomas in both the organs. Sample size (n)=3 guinea pigs in each group.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Data used for generating the plot in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig2-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig2-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Hepatocytes provide a replicative niche to Mtb</title><p>Consistent data from human TB patients and aerosol murine model prompted us to develop an in vitro model of Mtb and hepatocyte infection. We examined Mtb infection in several hepatocyte cell lines of mouse and human origin, along with primary murine hepatocytes. Infection studies with fluorescently labeled Mtb <italic>H37Rv</italic> were carried out with primary murine hepatocyte cells (PHCs), HepG2, Huh-7, and AML-12 (<xref ref-type="fig" rid="fig3">Figure 3A, B and C</xref>). The multiplicity of infection was titrated both in PHCs and HepG2 with the MOI of 1, 2.5, 5, and 10. MOI 10 consistently showed an infectivity of more than 60% in both HepG2 and PHCs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B and C</xref>). While we acknowledge that MOI 10 is moderately high, several well-cited studies have used MOI 10 for various conventional phagocytes and other non-conventional cell types like mesenchymal stem cells, adipocytes, and human lymphatic endothelial cells (<xref ref-type="bibr" rid="bib29">Jain et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Lerner et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Kalam et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Peyron et al., 2008</xref>; <xref ref-type="bibr" rid="bib7">Beigier-Bompadre et al., 2017</xref>). Hence, MOI 10 was selected for further experiments. Macrophage cell lines RAW 264.7, THP-1, and mouse bone marrow-derived macrophages (BMDMs) were used as positive controls. Even though PHCs, HepG2, Huh-7, and AML-12 are not considered to be classical phagocytic cells, all cells showed infectivity of more than 60% after 24 hr, comparable to RAW 264.7, THP-1, and BMDMs (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Analysis of bacterial load in the PHCs post-infection showed colony-forming units (CFU) like RAW 264.7, THP-1, and BMDMs, supporting microscopic observations (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Mtb in macrophages is known to remodel the intracellular environment to survive within phagosomes. We studied Mtb growth kinetics within hepatocytes using GFP-labeled Mtb <italic>H37Rv</italic> in PHCs and HepG2 (<xref ref-type="fig" rid="fig3">Figure 3D and F</xref>). Mean fluorescent intensity measurements showed a consistent increase in GFP intensity in both PHCs and HepG2 with increasing time (<xref ref-type="fig" rid="fig3">Figure 3E and G</xref>). Fold change in replication dynamics with respect to 5 hr post-infection (HPI) showed that, while bacterial growth in macrophages plateaus after 48 hr post-infection, Mtb continues to grow in both HepG2 and PHCs (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Relative CFU numbers in the PHCs and HepG2 further supports our data (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D-H</xref>). Our studies thus establish that hepatocytes, besides being robustly infected by Mtb, also provide a favourable replicative niche for Mtb.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Mycobacterium tuberculosis</italic> (Mtb) uses hepatocytes as a replicative niche.</title><p>(<bold>A and B</bold>) Representative microscopic images showing the infection of primary hepatocytes (PHCs), AML-12, HepG2, and Huh-7 with labeled Mtb-H37Rv strains and subsequent quantification of percentage infectivity in the respective cell types. RAW 264.7, THP-1, and murine bone marrow-derived macrophages (BMDMs) were used as macrophage controls. The scale bar in all images is 10 µm except in HepG2, which is 5 µm (<bold>C</bold>) colony-forming unit (CFU) enumeration of Mtb-H37Rv in different hepatic cell lines. (<bold>D and E</bold>) Representative confocal microscopy images of Mtb-GFP-H37Rv infected PHCs at the respective time points post-infection and bar blot depicting mean fluorescent intensity (MFI)/cell at the respective time points. (<bold>F and G</bold>) Representative confocal microscopy images of MtbH37Rv-GFP infected HepG2 at the respective time points post-infection and bar blot depicting MFI/cell at the respective time points, n=4 independent experiments, with each dot representing five fields of 30–60 cells. Scale bar 10 µm. (<bold>H</bold>) Fold change of growth rate of Mtb within HepG2, PHCs, RAW 264.7, THP-1, and BMDMs at the mentioned time points post-infection. All the figures show representative data from four independent biological experiments.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig3">Figure 3E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig3">Figure 3G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><label>Figure 3—source data 5.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig3">Figure 3H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-data5-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Standardization of multiplicity of infection (MOI) in primary hepatocytes (PHCs) and HepG2.</title><p>(<bold>A</bold>) Confocal microscopic images of Phalloidin Alexa Fluor 555-stained PHCs infected with different multiplicity of infection (MOI) of Mtb-H37Rv-GFP. (<bold>B</bold>) Quantification of % infectivity at different MOIs in primary hepatocytes (PHCs) (<bold>C</bold>) Quantification of % infectivity at different MOIs in HepG2. Relative CFU of Mtb in (<bold>D</bold>) HepG2, (<bold>E</bold>) PHCs, (<bold>F</bold>) RAW 264.7, (<bold>G</bold>) THP-1, (<bold>H</bold>) murine BMDMs at the respective time points post-infection.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Data used for generating <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Data used for generating <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-figsupp1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata3"><label>Figure 3—figure supplement 1—source data 3.</label><caption><title>Data used for generating <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-figsupp1-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata4"><label>Figure 3—figure supplement 1—source data 4.</label><caption><title>Data used for generating <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-figsupp1-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata5"><label>Figure 3—figure supplement 1—source data 5.</label><caption><title>Data used for generating <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-figsupp1-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata6"><label>Figure 3—figure supplement 1—source data 6.</label><caption><title>Data used for generating <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-figsupp1-data6-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata7"><label>Figure 3—figure supplement 1—source data 7.</label><caption><title>Data used for generating <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig3-figsupp1-data7-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Transcriptomics of infected hepatocytes reveal significant changes in key metabolic pathways</title><p>To understand Mtb-induced changes in the hepatocytes and the underlying mechanisms of how hepatocytes provide a favourable environment to the pathogen, we performed transcriptomic analysis of the infected and sorted HepG2 cells at 0 hr (5 hr post-incubation) and 48 hr post-infection. Sorting before RNA isolation specifically enriches the infected cellular population, thus eliminating cellular RNA from uninfected cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Unsupervised clustering segregated the data into 4 distinct groups on the PC1 with a variance of 27 %, showing good concordance within the replicates (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The close spatial clustering for the two 0 hr time points corresponding to uninfected and infected is indicative of relatively less transcriptomic changes. On the other hand, the spatial segregation of the 48 hr datasets suggests clear differences between the RNA transcripts of uninfected and infected cells. The differentially expressed genes were calculated using DESeqR with fold change &gt;0.5 and a false discovery rate of &lt;0.2. Gene ontology (GO) enrichment analysis for the differentially regulated pathways at both the early (0 hr) and the late (48 hr) infection time points is shown in (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). At 0 hr post-infection, the immediate stress response pathway of the cell, involving ROS generation, intracellular receptor signaling pathways, and response to xenobiotic stresses got activated, while at a late time point, Mtb modulated some of the key immuno-metabolic pathways like macroautophagy, cellular respiration, proteasomal degradation pathway, response to type I interferon, IκB kinase/NF-κB signaling, etc (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Major alterations in the vacuolar and vesicular transport at 48 hr are indicative of the dynamic changes in the phagosome maturation pathway (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Volcano plot analysis showed greater relative changes in the gene expression pattern at 48 hr compared to 0 hr, with many genes like <italic>CXCL10, CXCL11, IDO, CCL5,</italic> etc being greatly upregulated (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>). Interestingly, our RNA sequencing data indicated major changes in various facets of lipid metabolic pathways like fatty acid biosynthesis pathway, glycerolipid and glycerophospholipid metabolism, cholesterol biosynthesis pathways, etc. Several key genes like <italic>FASN, DGAT1, DGAT2</italic>, <italic>HMGCR</italic>, etc., were upregulated, indicating the possibility of greater synthesis of neutral lipids. Additionally, we have added a supplementary excel file with top 1000 differentially expressed genes (DEGs) at both 0 hr and 48 hr post-infection (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Thus, transcriptomic studies shed light on several of the key Mtb-induced changes in the hepatocytes.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>RNA sequence analysis of infected and sorted hepatocytes at 0 hr and 48 hr post-infection.</title><p>(<bold>A</bold>) Experimental setup for infection of HepG2 with Mb-H37Rv-mCherry at 10 multiplicity of infection (MOI) with histogram of mCherry signals at 0- and 48 hr post-infection (schematic depicting experimental setup generated using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/xivj47p">Biorender.com</ext-link>) (<bold>B</bold>) Principal component analysis (PCA) plot illustrating the HepG2 transcriptome, identified through global transcriptomic analysis of 0 hr uninfected and infected and 48 hr uninfected and infected. (<bold>C</bold>) Gene ontology (GO) pathway enrichment analysis was done for differentially expressed genes (DEGs) with adjusted <italic>o</italic>-value &lt;0.05 at 0- and 48 hr post-infection. The bubble plot depicts the enrichment of pathways on the mentioned time points post-infection, where the coordinate on the x-axis represents the gene ratio, the bubble size represents the gene count, and color represents the p-value. (<bold>D and E</bold>) Volcano plot depicting the fold change of different genes in 0 hr and 48 hr post-infection, the red dots represent the significantly upregulated and downregulated genes.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Data used to generate the volcano plot in <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Data used to generate the volcano plot in <xref ref-type="fig" rid="fig4">Figure 4E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig4-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Comparison of significant pathways between <italic>Mycobacterium tuberculosis</italic> (Mtb)-infected THP-1 and HepG2, 48 HPI.</title><p>(<bold>A</bold>) Gene ontology (GO) pathway enrichment analysis was done for differentially expressed genes (DEGs) with adjusted <italic>p</italic>-value &lt;0.05 at 48 hr post-infection for Mtb-infected THP-1. (<bold>B</bold>) GO pathway enrichment analysis was done for DEGs with adjusted <italic>p</italic>-value &lt;0.05 at 48 hr post-infection for Mtb-infected HepG2. The bubble plot depicts the enrichment of pathways on the mentioned time points post-infection, where the coordinate on the x-axis represents the gene ratio, the bubble size represents the gene count and color represents the p-value The bubble plot depicts the enrichment of pathways on the mentioned time points post-infection, where the coordinate on the x-axis represents the gene ratio, the bubble size represents the gene count and color represents the p-value.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig4-figsupp1-v1.tif"/></fig></fig-group><p>To understand the difference and similarities between the pathways that get affected in macrophages compared to hepatocytes during Mtb infection, we compared the gene expression analysis data from Mtb-infected HepG2, 48 hr post-infection with THP-1 infected macrophages, 48 post-infection, taken from <xref ref-type="bibr" rid="bib31">Kalam et al., 2017</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>. The comparison provides insights regarding how Mtb modulates different pathways depending on the type of the host cell infected. In THP-1, most of the altered pathways are related to mounting an effective immune response to the bacteria like type 1 interferon signalling pathway, regulation of cytokine secretion, leukocyte chemotaxis, response to zinc, etc, while in HepG2 the pathways that are getting altered are related to metabolism like response to xenobiotic stimulus, macroautophagy, glycerophospholipid and glycerolipid metabolism, and cellular respiration. This comparative analysis is indicative of Mtb’s ability to harness the metabolic richness of hepatocytes, probably as a source for nutrients. Moreover, being a non-immune cell type, hepatocytes might lack a robust innate immune pathway like the macrophages and hence be less likely to clear mycobacterial infections.</p></sec><sec id="s2-5"><title>Increased fatty acid synthesis drives Mtb growth in hepatocytes</title><p>Mtb survival in foamy macrophages is driven by nutrient acquisition from the lipid droplets (<xref ref-type="bibr" rid="bib45">Peyron et al., 2008</xref>). Transcriptomic studies of Mtb-infected cells also showed upregulated pathways for lipid metabolism. Examination of Lipid droplets in both PHCs and HepG2 revealed an increase in the number of lipid droplets at 24 hr post-infection (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). Time kinetic analysis of BODIPY intensity in the infected HepG2 at different days post-infection indicated a concomitant increase in lipid droplets with the progress of infection (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Moreover, in PHCs, GFP-labeled Mtb showed a high degree of colocalization with the lipid droplets (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Lipid droplets are single membrane-bound depots consisting mainly of neutral lipids like diacylglycerols (DAGs), triacylglycerols (TAGs), and cholesterol esters (CEs) (<xref ref-type="bibr" rid="bib60">Wölk and Fedorova, 2024</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Increased fatty acid biogenesis drives <italic>Mycobacterium tuberculosis</italic> (Mtb) growth in hepatocytes.</title><p>(<bold>A</bold>) Increased number of LDs/cells in HepG2 and primary hepatocytes (PHCs) post-Mtb infection as compared to the uninfected cells (<bold>B</bold>) Quantification of the number of lipid droplets in the infected HepG2 and PHCs with their uninfected control, 50–70 cells were analyzed from 3 independent experiments. (<bold>C</bold>) Increase in the BODIPY intensity at different days post-infection in infected hepatocytes (<bold>D</bold>). A high degree of colocalization of Mtb-<italic>H37Rv-</italic>GFP (green) with lipid droplets (red) within PHCs (<bold>E</bold>) Mass spectrometric quantification of the different species of diacylglycerols (DAGs), triacylglycerols (TAGs), and cholesterol esters in the Mtb-infected hepatocytes. (<bold>F</bold>) Confocal images showing puncta of fluorescently labeled fatty acid in Mtb derived from metabolically labeled (with BODIPY 558/568 C<sub>12</sub>) HepG2. Relative colony-forming unit (CFU) of Mtb under the administration of different inhibitors of the lipid metabolic pathway in (<bold>G</bold>). PHCs (<bold>H</bold>). HepG2 and (<bold>I</bold>). THP-1. Representative data from three independent biological experiments. Data were analyzed using the two-tailed unpaired Student’s t-test in B and one-way ANOVA in C, F, G, and H.*<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;0.005, ***<italic>p</italic>&lt;0.0005, ****<italic>p</italic>&lt;0.0001. ns = non-significant. The figures represent data from three independent biological experiments.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig5-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Data used for generating the graphs in <xref ref-type="fig" rid="fig5">Figure 5E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig5-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig5">Figure 5G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig5-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig5">Figure 5H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig5-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata6"><label>Figure 5—source data 6.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig5">Figure 5I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig5-data6-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Increased lipid biogenesis provides a growth advantage to <italic>Mycobacterium tuberculosis</italic> (Mtb) within hepatocytes.</title><p>(<bold>A</bold>) Confocal microscopy showing the LDs in both primary hepatocytes (PHCs) and HepG2 under inhibitors of fatty acid biosynthesis and triacylglycerols (TAG) biosynthesis. (<bold>B</bold>) Mtb RNA isolated from DMEM grown Mtb and HepG2-derived Mtb,48 HPI, with the RNA expression pattern of key lipid biogenesis genes and TAG biosynthesis genes in Mtb as determined by qRT PCR, the fold change has been calculated by considering the expression in the DMEM grown Mtb to be 1 (<bold>C</bold>) Experimental plan for metabolic labeling of HepG2 and subsequent infection by Mtb (schematic of experimental procedure generated using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/vrll8j9">Biorender.com</ext-link>) (<bold>D</bold>) Fluorescently labeled fatty acid (BODIPY 558/568 C12) staining in DMSO-treated, C75-treated, and T863-treated HepG2. Data were analyzed by using the two-tailed unpaired Student’s t-test in B. *<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;0.005, ***<italic>p</italic>&lt;0.0005, ****<italic>p</italic>&lt;0.0001, ns = non-significant. Representative data from three biologically independent experiments.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Data used for generating <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Confocal microscopy images showing the puncta of fluorescently labeled fatty acid (BODIPY 558/568 C12) in <italic>Mycobacterium tuberculosis</italic> (Mtb) isolated from metabolically labeled HepG2.</title><p>(<bold>A</bold>) Confocal images showing puncta of labeled fatty acid in Mtb derived from DMSO, C75, and T863 treated metabolically labeled HepG2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Enhanced lipid accumulation in the liver of <italic>Mycobacterium tuberculosis</italic> (Mtb)-infected mice.</title><p>(<bold>A</bold>) BODIPY staining in the liver of the uninfected and 8 weeks post-Mtb-infected murine liver (<bold>B</bold>) Dual staining of BODIPY (green) and Ag85B (red) shows Ag85B colocalization with BODIPY (highlighted in the zoomed image). (<bold>C</bold>) Representative images showing the mean lipidTOX Neutral Red staining in infected liver, 2-, 4-, and 8 weeks post-infection (<bold>D</bold>) Plot depicting the mean lipidTOX intensity at the mentioned time points post-infection normalized to the area. Data were analyzed using one-way ANOVA. *<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;0.005, ***<italic>p</italic>&lt;0.0005, ****<italic>p</italic>&lt;0.0001. ns = non-significant in I. Representative data from experiment having n=4–6 mice/group.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5—figure supplement 3—source data 1.</label><caption><title>Data used for generating the plot <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig5-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig5-figsupp3-v1.tif"/></fig></fig-group><p>Mass-spectrometric analysis of the infected and uninfected HepG2 cells at 24 hr post-infection, showed an increase in both TAGs and DAGs and CEs with a decrease in the levels of free cholesterols, indicating Mtb-induced changes in the neutral lipid biosynthesis (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). To understand whether Mtb utilizes host lipid droplets as a source of nutrients in hepatocytes, we treated Mtb-infected hepatocytes with specific inhibitors of de novo fatty acid biosynthesis (C75) and TAG biosynthesis (T863) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Interestingly, inhibiting both de novo fatty acid biosynthesis as well as TAG biosynthesis reduced the bacterial load in both PHCs and HepG2 by almost 1.0–1.5 log fold (<xref ref-type="fig" rid="fig5">Figure 5G and H</xref>). In THP-1 macrophage, although C75 reduced bacterial load by 0.5 log fold but T863 did not affect the bacterial load (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). To get better insights into the nutritional dependency of intracellular Mtb on hepatocyte lipid source, we metabolically labeled HepG2 with 7.5 μg/ml of fluorescently tagged fatty acid (BODIPY 558/568 C<sub>12</sub>) which subsequently accumulated into host lipid droplets. After 16–20 hr, the labeled cells were treated with T863 and C75. Although T863 significantly reduced the load of the intracellular TAGs, C75 had little effect on the level of accumulated TAGs and showed a phenotype like the DMSO control (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>). We infected these three sets of cells with Mtb (MOI:10) for 24 hr. The Mtb isolated from DMSO and C75-treated HepG2 became distinctly labeled with highly fluorescent lipid bodies, but the fluorescence signal in Mtb derived from T863-treated cells was quite low and sparse (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>). Considering that host-derived fatty acids are converted to TAGs in the bacterial cytoplasm as a source of carbon and energy, we wanted to check whether the TAG synthesis machinery was modulated in the hepatocyte-infected Mtb. To this end, we isolated Mtb from HepG2, 48 hr post-infection, and analysed for key genes involved in TAG biosynthesis. Mtb grown in DMEM was used as a control. Interestingly, <italic>Tgs1, Tgs4, Rv 1760</italic>, etc, were upregulated by 6–8-fold, indicating an active Mtb transcriptional change in Mtb to utilize and store host-derived lipids (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Cumulatively, our studies thus demonstrate fatty acid biosynthesis and TAG formation to be important for Mtb growth in hepatocytes.</p><p>To assess the status of the neutral lipids in the liver, BODIPY staining was conducted in the liver cryosections of uninfected and infected mice (8 weeks post-infection). The liver of Mtb-infected mice bears more lipid bodies (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A</xref>). Co-immunostaining of BODIPY and Ag85B also showed abundant lipid droplets and specific signals of Ag85B (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3B</xref>). Next, we stained the liver of Mtb-infected mice at 2-, 4-, and 8 weeks post-infection with LipidTOX neutral red dye. Surprisingly we found an elevated signal intensity of the dye at 8 weeks post-infection. This shows that in mice, lipid droplets might correlate with Mtb burden (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3C, D</xref>). Our data comprehensively establishes infection-induced lipid droplet accumulation as a pathogenic outcome of Mtb involvement in the liver during the chronic stage of infection.</p></sec><sec id="s2-6"><title>PPARγ upregulation in Mtb-infected hepatocytes leads to augmented lipid biogenesis</title><p>To understand the molecular mechanism behind the accumulation of lipid droplets in the Mtb-infected liver at 8 weeks post-infection, we investigated the expression patterns of the transcription factors involved in the regulation of the genes of lipid biogenesis in our RNA-seq data. At 48 hr post-infection, the transcript levels of Peroxisome proliferator-activated receptor-gamma (<italic>PPARG</italic>) were upregulated by 5–6-fold. To validate, we performed quantitative real-time PCR analysis of the <italic>PPARG</italic> gene in the infected HepG2 at 48 hr post-infection. With respect to the uninfected control, <italic>PPARG</italic> was upregulated by 3–4-fold. Besides, downstream adipogenic genes that are directly or indirectly controlled by PPARγ protein like <italic>MGAT1</italic>, <italic>FSP27</italic>, <italic>FASN</italic>, <italic>DGAT1</italic>, <italic>DGAT2</italic>, <italic>ACAT1, ACAT2, ADIPSIN,</italic> etc were all upregulated by more than twofold in the infected cells. (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Immunoblot also revealed a greater level of PPARγ protein in primary mouse hepatocytes at 24 hr and 48 hr post-infection in the Mtb-infected cells (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). In the in vivo Mtb aerosol infection model, <italic>Pparg</italic> expression levels showed an intriguing trend, at week 2 post-infection, the expression level was comparable to the uninfected control, while at week 4 post-infection, the expression level spiked to 1.5–2-fold, reaching 3–4 fold at week 8 (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The pattern of expression of <italic>Pparγ</italic> in the infected liver correlated with the bacterial load in the liver, where we see the induction at week 4 when Mtb reaches the liver and maximum expression at week 8 when the load of Mtb is considerably high. Besides, PPARγ, some of the critical enzymes involved in fatty acid biosynthesis, TAG biosynthesis, cholesterol esterification like <italic>Fasn, Dgat1, Dgat2, Mgat1, Acat1, Acat2,</italic> etc., showed a temporal increase in expression levels at the later time points post-infection (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We then used a specific inhibitor of PPARγ, GW9662 (20 µM), and agonist of PPARγ, rosiglitazone (20 µM) in infected HepG2 and quantified the bacterial load after 48 hr. Importantly, inhibition of PPARγ decreased the bacterial load by almost twofold, while chemically inducing PPARγ increased the bacterial load considerably (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>, and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Moreover, LD numbers in cells also directly correlated with the levels of PPARγ (<xref ref-type="fig" rid="fig6">Figure 6G and H</xref>). To investigate whether <italic>Pparg</italic> expression was also induced in the liver of infected mice, we examined <italic>Pparg</italic> in the liver post-infection. Interestingly, we found enhanced expression PPARγ in the liver of the mice at 8 weeks post-infection (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C, D</xref>). Moreover, PPARγ protein intensity in hepatocytes was also high in the infected liver (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>). Thus, PPARγ activation resulting in lipid droplets formation by Mtb might be a mechanism of prolonging survival within hepatocytes.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Peroxisome proliferator-activated receptor-gamma (PPARγ) driven lipid biogenesis drives <italic>Mycobacterium tuberculosis</italic> (Mtb) growth in hepatocytes.</title><p>(<bold>A</bold>) Heat map showing the fold change of the genes involved in the lipid biosynthesis and LD biogenesis in liver across weeks 2, 4, and 8, post-infection. (<bold>B</bold>) Kinetic increase in the gene expression of <italic>Pparγ</italic> transcript levels across different weeks post-infection (<bold>C</bold>) Immunoblot showing increased PPARγ protein levels in primary hepatocytes (PHCs) (MOI: 10) at 5-, 24-, and 48 hr post-infection. (<bold>D</bold>) Bar plot showing the increased band intensity of PPARγ in the infected PHCs at the mentioned time points. (<bold>E</bold>) Representative confocal microscopy images showing HepG2 infected with Mtb-mCherry-<italic>H37Rv</italic> and treated with GW9662 and rosiglitazone (<bold>F</bold>) mean fluorescent intensity (MFI)/cell of Mtb-mCherry-<italic>H37Rv</italic> DMSO-treated, GW9662, and rosiglitazone-treated HepG2 cells. (<bold>G</bold>) Representative confocal images of uninfected, infected, GW9662, and rosiglitazone-treated infected HepG2 showing changes in the number of LDs. (<bold>H</bold>) Plot depicting the quantification of LDs/cell in the mentioned conditions. Representative data from n=4 biological replicates. Data were analyzed by using the two-tailed unpaired Student’s t-test in D and by one-way ANOVA in B, F, and H. *<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;0.005, ***<italic>p</italic>&lt;0.0005, ****<italic>p</italic>&lt;0.0001, ns = non-significant.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Data used for generating the heatmap in <xref ref-type="fig" rid="fig6">Figure 6A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Labeled and unedited blots shown in <xref ref-type="fig" rid="fig6">Figure 6C</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-103817-fig6-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig6">Figure 6D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata5"><label>Figure 6—source data 5.</label><caption><title>Data used for generating the plot in <xref ref-type="fig" rid="fig6">Figure 6F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata6"><label>Figure 6—source data 6.</label><caption><title>Data used for generating the plot in <xref ref-type="fig" rid="fig6">Figure 6H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-data6-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title><italic>Mycobacterium tuberculosis</italic> (Mtb) induced peroxisome proliferator-activated receptor-gamma (PPARγ) expression in infected hepatocytes.</title><p>(<bold>A</bold>) mRNA levels of <italic>PPARG</italic> and other lipid biosynthetic genes in infected HepG2, the fold change has been calculated by considering the expression in the uninfected cell to be 1 (<bold>B</bold>) Relative bacterial burden in DMSO, GW9662, and rosiglitazone-treated HepG2 infected with Mtb H37Rv. (<bold>C</bold>) Multiplex immunostaining showed increased expression of PPARγ in the liver of infected mice, 8 weeks post-infection. (<bold>D</bold>) Bar plot showing PPARγ protein intensity (normalized to the area) in the uninfected and infected liver, 8 weeks post-infection. (<bold>E</bold>) Intensity of PPARγ protein per hepatocyte in uninfected and infected liver, 8 week post-infection. Data were analyzed by using the two-tailed unpaired Student’s t-test in (A, D, and E) and by one-way ANOVA in B. Representative data from n=4 biological replicates *<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;0.005, ***<italic>p</italic>&lt;0.0005, ****<italic>p</italic>&lt;0.0001. ns = non-significant.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-figsupp1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata3"><label>Figure 6—figure supplement 1—source data 3.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-figsupp1-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata4"><label>Figure 6—figure supplement 1—source data 4.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig6-figsupp1-data4-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Hepatocyte resident Mtb displays a drug-tolerant phenotype</title><p>The success of Mtb as a formidable pathogen depends on its ability to tolerate various anti-TB drugs (<xref ref-type="bibr" rid="bib17">Day et al., 2024</xref>). Drug tolerance is a phenomenon of Mtb surviving drug treatment of longer durations in the absence of any resistance mechanisms. It is a property exhibited by the bacteria but is influenced by both the host and the bacterial factors (<xref ref-type="bibr" rid="bib15">Datta et al., 2024</xref>). Interestingly, hepatocytes are a unique cell type that contains phase I and phase II drug metabolising enzymes (<xref ref-type="bibr" rid="bib2">Almazroo et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Ahmed et al., 2016</xref>). The pharmacological potency of lipophilic drugs is determined by the rate at which these drugs are metabolized to inactive products.</p><p>Cytochrome P450 monooxygenases (cyp450s) system is the key phase I DMEs and known to interact with rifampicin (<xref ref-type="bibr" rid="bib23">Fisher et al., 2009</xref>). We, therefore, analysed whether Mtb infection influences the cyp genes in hepatocytes. <italic>CYP3A4</italic> and <italic>CYP3A43,</italic> respectively, both of which metabolize anti-TB drug rifampicin were upregulated in Mtb-infected HepG2 by approximately fourfold and twofold, respectively (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). Moreover, <italic>NAT2</italic> gene responsible for N-acetylation of isoniazid was also upregulated in the Mtb-infected HepG2 by almost twofold (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). We, therefore, argued that hepatocyte-resident Mtb may display higher tolerance to rifampicin. Towards this, we treated Mtb-infected HepG2 and PHCs with different concentrations of Rifampicin (0.1, 0.5, 5 µg/ml) for 24 hr and CFU enumerated the bacterial after lysis. RAW 264.7 was kept as macrophage control with the similar experimental setup. The percentage of bacteria which survived the drugs was the drug-tolerant population. Both HepG2 and PHCs resident Mtb were significantly tolerant to (25–30%) to rifampicin, as compared to the macrophages (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). Almost 10 % of the bacterial population in HepG2 display a tolerogenic phenotype at the highest antibiotic concentration (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Hepatocytes provide a drug-tolerant niche to <italic>Mycobacterium tuberculosis</italic> (Mtb).</title><p>(<bold>A</bold>) Experimental scheme of deducting the percentage drug tolerance in hepatocytes (generated using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/9pk0z0n">Biorender.com</ext-link>) (<bold>B</bold>) Percentage tolerance of Mtb-H37Rv against Rifampicin within RAW 264.7, primary hepatocytes (PHCs), and HepG2 at different time points post-infection. (<bold>C</bold>) Percentage tolerance of Mtb-H37Rv against Isoniazid within RAW 264.7, PHCs, and HepG2 at different time points post-infection. Representative data from three independent experiments. (<bold>D</bold>) Percentage tolerance of Mtb-<italic>H37Rv</italic> against rifampicin within bone marrow-derived macrophages (BMDMs), PHCs, and HepG2 as measured microscopically (<bold>E</bold>) Percentage tolerance of Mtb-H37Rv against isoniazid within BMDMs, PHCs, and HepG2 measured microscopically. Representative data from three independent experiments. Each dot represents a single field having more than four infected cells. 20 such fields were analyzed (<bold>F</bold>) Transcript levels of the various drug modifying enzymes (DMEs) involved in Rifampicin and Isoniazid metabolism in mice liver, 8 weeks post-infection (n=4 mice), the fold change has been calculated by considering the expression in the uninfected mice to be 1. Data were analyzed by using two-way ANOVA in (<bold>B</bold>) and (<bold>C</bold>), one-way ANOVA in (<bold>D</bold>) and (<bold>E</bold>) and the two-tailed unpaired Student’s t-test in (<bold>F</bold>) and Representative data from n=4 biologically independent replicates *<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;0.005, ***<italic>p</italic>&lt;0.0005, ****<italic>p</italic>&lt;0. 0001. ns=non-significant.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig7">Figure 7B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig7-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig7">Figure 7C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig7-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Data used for generating the plot in <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig7-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata4"><label>Figure 7—source data 4.</label><caption><title>Data used for generating the plot in <xref ref-type="fig" rid="fig7">Figure 7E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig7-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata5"><label>Figure 7—source data 5.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig7">Figure 7F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig7-data5-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Gene expression analysis of key drug modifying enzymes (DMEs) related to rifampicin and isoniazid metabolism.</title><p>(<bold>A</bold>) Relative expression of <italic>CYP3A4, CYP3A43,</italic> and <italic>NAT2</italic> genes in infected HepG2 post-Mtb infection, the fold change has been calculated by considering the expression in the uninfected cells to be 1. Data were analyzed using the two-tailed unpaired Student’s t-test in C. *<italic>p</italic>&lt;0.05, **p&lt;0.005, ***p&lt;0.0005, ****p&lt;0.0001, ns = non-significant. (<bold>B</bold>) KEGG pathway analysis shows the upregulation of <italic>NAT2</italic> gene (N-acetyltransferase 2) in <italic>Mycobacterium tuberculosis</italic> (Mtb)-infected HepG2.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig7-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Microscopic images of <italic>Mycobacterium tuberculosis</italic> (Mtb)-infected bone marrow-derived macrophages (BMDMs), primary hepatocytes (PHCs), and HepG2 treated with rifampicin and isoniazid.</title><p>(<bold>A</bold>) Confocal microscopy images of Mtb-H37Rv-GFP infected BMDMs, PHCs, and HepG2. All the cells are treated with DMSO, 0.5 μg/ml rifampicin, and 0.5 μg/ml isoniazid post-infection. The cells were stained with Phalloidin Alexa Fluor-555 to demarcate the cell boundary. Representative data from three biologically independent experiments. Each dot represents a single field having more than four infected cells. 20 such fields were analyzed.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig7-figsupp2-v1.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title><italic>Mycobacterium tuberculosis</italic> (Mtb) derived from hepatocytes show no changes in drug efflux pumps and antibiotic sensitivity.</title><p>(<bold>A</bold>) Resazurin microtitre assay of the three groups of Mtb in different concentrations of isoniazid and rifampicin (schematic of experimental procedure generated using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/shsj3cu">Biorender.com</ext-link>). (<bold>B</bold>) Mtb was obtained from DMSO-treated, 0.5 μg/ml rifampicin, and 0.5 μg/ml isoniazid-treated HepG2 by differential lysis and RNA was isolated from those Mtb populations (<bold>C and D</bold>) qRT-PCR of some of the key efflux pumps genes in these three Mtb groups. Representative data from three biologically independent experiments. Data were analysed using the two-tailed unpaired Student’s t-test in C and D. *<italic>p</italic>&lt;0.05, **<italic>p</italic>&lt;112 0.005, ***<italic>p</italic>&lt;0.0005, ****<italic>p</italic>&lt;0.0001, ns = non-significant. Representative data from three biological replicates.</p><p><supplementary-material id="fig7s3sdata1"><label>Figure 7—figure supplement 3—source data 1.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig7-figsupp3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7s3sdata2"><label>Figure 7—figure supplement 3—source data 2.</label><caption><title>Data used for generating the graph in <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103817-fig7-figsupp3-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-fig7-figsupp3-v1.tif"/></fig></fig-group><p>We also examined Mtb susceptibility to isoniazid (INH), another first-line anti-TB drug which is predominantly metabolized (50–90%) via N-acetylation of its hydrazine functionality by arylamine N-acetyltransferase 2 (NAT2) (<xref ref-type="bibr" rid="bib55">Sotsuka et al., 2011</xref>). Interestingly, KEGG analysis of transcriptomic data suggested several genes in this pathway to be upregulated in hepatocytes infected with Mtb (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). Experimental studies indeed showed higher tolerance of Mtb to INH in both primary hepatocytes and HepG2 at different concentrations (0.1, 0.5, 5 µg/ml) (<xref ref-type="fig" rid="fig7">Figure 7A and C</xref>). To corroborate the CFU data, we repeated the same experiment (<xref ref-type="fig" rid="fig7">Figure 7A</xref>) and looked at the bacterial load within each of murine PHCs and BMDMs using high-resolution confocal microscopy. Mouse BMDMs were used as a macrophage control. Here also we have calculated the percentage tolerance as a ratio by measuring the mean fluorescent intensity of GFP-Mtb per hepatocyte treated with drug to MFI of GFP-Mtb per hepatocyte treated with DMSO (control). Extensive analysis of more than 200 cells distinctly showed the presence of more Mtb within PHCs treated with both rifampicin and isoniazid than in BMDMs treated with the same concentration of the drugs (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>).</p><p>To check whether some of these key DMEs are also altered in the Mtb-infected mice liver, we did qRT-PCR of some key DMEs related to both rifampicin and isoniazid metabolism. Transcript levels of some of the key DMEs were upregulated in the liver of the infected mice, 8 weeks post-infection like <italic>Nat2, Cyp2e1, Slco1b2</italic>, <italic>Ces1, Ces2, and Aadac</italic> (upregulated by almost 2–3-fold) (<xref ref-type="fig" rid="fig7">Figure 7F</xref>).</p><p>Drug tolerance is a bacterial property influenced by both bacterial and host-induced factors. To check whether Mtb derived from hepatocytes, post-drug exposure has altered drug sensitivity or not, we conducted a resazurin microtitre assay with different dilutions of both rifampicin and isoniazid with Mtb derived from PHCs treated with DMSO, Mtb derived from PHCs post-exposure to rifampicin and Mtb derived from PHCs post-exposure to isoniazid. Mtb from all three different setups did not show any alterations in their MIC values, displaying no change in drug sensitivity (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A</xref>). The increased tolerance of Mtb within the hepatocytes can also be attributed to the increased activity of the drug efflux pumps. Drug efflux pumps like Rv1258c, Rv1410, and Rv1819c are known to get upregulated under drug stress conditions, preventing the accumulation of the drugs and thereby decreasing drug sensitivity. To this end, we isolated intracellular Mtb RNA from HepG2 treated with DMSO, 0.5 μg/ml rifampicin, and 0.5 μg/ml isoniazid and checked for the expression of key drug efflux pumps like <italic>Rv 1258 c. Rv1410, Rv1819</italic> etc in these three Mtb populations (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3B, C and D</xref>). Interestingly, quantitative RT-PCR analyses of these Mtb genes did not show any upregulation of these transporters in Mtb derived from HepG2 exposed to rifampicin and isoniazid, indicating that drug tolerance phenotype can be better attributed to host intrinsic factors rather than Mtb efflux pumps. Our data show that Mtb-infection of hepatocytes induces DMEs, and this host-specific extrinsic activation may result in decreased bioavailability or increased inactivation of anti-TB drugs.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Over the years, various anatomical and cellular environments conducive to Mtb infection have been identified, particularly concerning its latency (<xref ref-type="bibr" rid="bib14">Cosma et al., 2003</xref>; <xref ref-type="bibr" rid="bib10">Bussi and Gutierrez, 2019</xref>). Pulmonary TB typically presents with classical symptoms such as persistent coughing and mucus production due to lung involvement (<xref ref-type="bibr" rid="bib39">Luies and du Preez, 2020</xref>). While systemic manifestations like weight loss, fatigue, and loss of appetite are commonly linked to TB progression, the underlying factors driving these metabolic derangements remain unexplored. Our study sheds light on hepatocytes as a previously unrecognized site for Mtb survival and replication, thereby extrapolating the current understanding of TB beyond its pulmonary focus. By combining in vitro, ex vivo, in vivo, and clinical data, we demonstrate that Mtb not only persists within hepatocytes but also induces important metabolic reprogramming, with significant implications for disease progression, symptomatic manifestations, and drug tolerance.</p><p>A central finding of our work is the Mtb-mediated activation of peroxisome proliferator-activated receptor gamma (PPARγ) in hepatocytes. PPARγ activation leads to the accumulation of cholesterol esters (CE 16:0, 18:0, 18:1), diacylglycerols (DAGs 36:1, 36:2, 34:1), and triacylglycerols (TAGs 18:1/36:2, 18:0/36:2, 18:0/36:1). These lipid pools contribute to the formation of lipid droplets, which colocalize with intracellular Mtb, serving as a nutrient reservoir that facilitates bacterial persistence and proliferation. The upregulation of key TAG biosynthesis genes such as <italic>Tgs1</italic>, <italic>Tgs4</italic>, and <italic>Rv1760</italic> in Mtb residing within hepatocytes underscores a transcriptional rewiring within the pathogen to assimilate lipids as a source of their nutrients. Our pharmacological studies using PPARγ agonist and antagonist demonstrated that modulation of PPARγ directly impacts Mtb burden in hepatocytes, confirming the pivotal role of PPARγ in Mtb survival in hepatocytes. The lipid remodeling induced by Mtb infection in hepatocytes is recapitulated in the murine aerosol model, where an increased number of lipid droplets was observed at week 8, accompanied by localized accumulation of immune cells and granuloma-like structures. These findings are consistent with previous reports in macrophages where PPARγ activation enhances lipid biosynthesis, regulates immune responses, and impedes host cell apoptosis (<xref ref-type="bibr" rid="bib4">Arnett et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Rajaram et al., 2010</xref>). Recent findings have further underscored heightened levels of PPARγ in peripheral blood mononuclear cells (PBMCs) from TB patients with elevated cortisol levels and increased disease severity (<xref ref-type="bibr" rid="bib20">Díaz et al., 2023</xref>). However, hepatocytes are uniquely positioned in systemic lipid regulation, engaging in de novo fatty acid synthesis, TAG synthesis, β-oxidation, and lipoprotein metabolism (<xref ref-type="bibr" rid="bib64">Zhang et al., 2022</xref>; <xref ref-type="bibr" rid="bib6">Bechmann et al., 2012</xref>). Mtb-mediated perturbation of these vital processes can lead to a sequela of metabolic disorders such as non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and insulin resistance. In macrophages, heightened intracellular lipid levels have been observed to impede autophagy and the acidification of phagolysosomes, both crucial for bacterial eradication (<xref ref-type="bibr" rid="bib37">Lovewell et al., 2016</xref>). Despite these parallels, comparative transcriptomic analyses of infected HepG2 cells with THP1 cells highlight differences in pathways such as vacuolar and vesicular transport, xenobiotic metabolism, macroautophagy, and cellular respiration. Furthermore, hepatocytes secrete hepatokines, a class of proteins serving as signaling molecules, with diverse roles in metabolism, inflammation, and energy homeostasis, thereby influencing the host-pathogen interplay (<xref ref-type="bibr" rid="bib30">Jensen-Cody and Potthoff, 2021</xref>). Intriguingly, a recent investigation demonstrated that hepatic PPARγ activation induces the expression of growth differentiation factor 15 (GDF-15), a crucial regulator of weight loss observed in ketogenic diets (<xref ref-type="bibr" rid="bib38">Lu et al., 2024</xref>).</p><p>Additionally, we suggest that Mtb infection of hepatocytes creates a drug-tolerant environment in the liver due to activation of DMEs, many of which are earlier shown to metabolize the two frontline drugs, isoniazid and rifampicin. Moreover, lipid accumulation in the liver might also indirectly alter the levels of drug metabolizing enzymes as reported in previous studies (<xref ref-type="bibr" rid="bib23">Fisher et al., 2009</xref>; <xref ref-type="bibr" rid="bib48">Rey-Bedon et al., 2022</xref>). Upregulation of transcripts is not only observed in infected cells in vitro, but also in the livers of mice eight weeks after Mtb infection. Particularly noteworthy is the upregulation of <italic>NAT-2</italic>, which controls the rate-limiting step of acetylating isoniazid into acetylisoniazid. This metabolite is further processed into acetylhydrazine and isonicotinic acid, ultimately reducing the drug’s effectiveness against Mtb. Similarly, key rifampicin-metabolizing esterase genes such as <italic>Ces1</italic>, <italic>Ces2</italic>, <italic>Aadac</italic>, and transporter <italic>Slco1b2</italic> exhibit upregulation, potentially influencing the drug’s distribution and metabolism in the body. The activation of DMEs can significantly modify the pharmacokinetics and pharmacodynamics of anti-TB medications, resulting in suboptimal drug concentrations and the emergence of drug-resistant strains (<xref ref-type="bibr" rid="bib21">Dookie et al., 2018</xref>).</p><p>Pulmonary TB can lead to miliary through hematogenous dissemination, where Mtb spreads from the infected lungs into blood vessels either from a primary lung focus, reactivated TB, or caseous necrosis. Once in blood vessels, the bacteria seed multiple organs, forming tiny granulomas, characteristic of miliary TB. The liver becomes involved either through direct hematogenous spread or extension from nearby infected lymph nodes, leading to hepatic TB, which presents with granulomas and liver dysfunction. This systemic spread underscore the severity of untreated pulmonary TB and the need for early intervention (<xref ref-type="bibr" rid="bib53">Shiloh, 2016</xref>; <xref ref-type="bibr" rid="bib13">Coleman et al., 2022</xref>; <xref ref-type="bibr" rid="bib59">Wei et al., 2024</xref>; <xref ref-type="bibr" rid="bib40">McMullan and Lewis, 2017</xref>). Our murine and guinea pig aerosol infection models demonstrated progressive liver involvement starting at week 4, with the presence of lipid-laden hepatocytes, localized immune infiltrates, and granuloma-like structures. Importantly, liver biopsy samples from TB patients revealed ectopic granulomas and Mtb antigen (Ag85B) localization within hepatocytes, highlighting the clinical relevance of our findings. While previous research has explored liver infection by Bacillus Calmette-Guérin (BCG) using an intravenous model in mice, the bacilli were predominantly found within tissue-resident macrophages or Kupffer cells at 15 min and 2 days post-infection (<xref ref-type="bibr" rid="bib51">Seiler et al., 2001</xref>). However, our study consistently identified the presence of Mtb within hepatocytes in a murine aerosol infection model after the fourth week. Similarly, in a guinea pig aerosol infection model, liver infection was evident, marked by distinct granulomas by week 4. Furthermore, analysis of human biopsy liver samples from pulmonary TB patients revealed ectopic granuloma-like structures within the liver hepatocytes, with the presence of Mtb-specific Ag85B signals within hepatocytes. Together, these findings underscore hepatocytes as a novel niche for Mtb persistence, shedding new light on the pathogenesis of TB. Interestingly, in infected armadillos, <italic>M. leprae</italic> is shown to infect hepatocytes and hijack liver homeostatic, regeneration pathways to promote de novo organogenesis (<xref ref-type="bibr" rid="bib26">Hess et al., 2022</xref>).</p><p>Although animal models offer valuable insights into Mtb infection and TB pathology, they fall short of fully replicating the complexities of human TB. Several recent studies in COVID-19 patients have shown that hepatocytes get infected with SARs-CoV-2, thereby increasing gluconeogenesis and hyperglycemia (<xref ref-type="bibr" rid="bib5">Barreto et al., 2023</xref>; <xref ref-type="bibr" rid="bib41">Mercado-Gómez et al., 2022</xref>). With compelling reports associating hepatic steatosis with the onset of type 2 diabetes mellitus (T2DM), we speculate that TB-induced perturbations in lipid metabolism might predispose chronic TB patients to T2DM and vice versa (<xref ref-type="bibr" rid="bib25">Hazlehurst et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Dharmalingam and Yamasandhi, 2018</xref>). Through our investigation, we propose that future studies in human TB patients might scrutinize this metabolically rich hepatocyte niche to understand multiple organ-wide derangements in TB pathogenesis.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Confocal microscopy and Immunofluorescence measurements</title><p>Lipid droplets were stained with BODIPY 493/503 dye. Primary mouse hepatocytes and HepG2 cells were grown on 12 mm coverslips at respective densities as per the experimental requirement. Cells were washed with 1X PBS (HiMedia M1452-500G), fixed with 4% paraformaldehyde, and incubated at room temperature for 15 min. After incubation, the cells were washed thrice with 1X PBS followed by staining with 10 μM BODIPY dye in 1X PBS for 45 min at room temperature. After the staining, the excess dye was removed by washing thrice with 1X PBS. To check for the acidified compartments within the cells, LysoTracker Red DND-99 (L7528) was added to the cells at a concentration of 500 nM for 30 min at 37°C, followed by washing thrice with 1X PBS to remove the residual dye. The cells were fixed with 4% paraformaldehyde as previously mentioned. For staining with various antibodies, the cells were permeabilized with 0.2% Triton-x 100 (X-100-1L) for 15 min, followed by proper washing with 1X PBS. The cells were then blocked by 2% BSA in 1X PBST for 1 hr at room temperature. Post blocking, the cells were treated with primary antibody overnight at 4°Celsius, followed by proper washing with 1X PBS. Secondary antibody (1:500 dilution) was added to the cells for 1 hr at room temperature. Three washes with 1X PBS were given. The nucleus was stained with DAPI (Sigma D9542-5MG) at 1ug/ml concentration for 20 min at room temperature. The excess DAPI was washed with 1X PBS followed by mounting with ProLong Gold Antifade mountant (P36930). Images were acquired by Zeiss LSM 980 Laser scanning confocal microscope.</p></sec><sec id="s4-2"><title>Image analysis</title><p>Analysis was done using Image J (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_003070">SCR_003070</ext-link>) and Zeiss Zen Microscopy software (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_013672">SCR_013672</ext-link>). Mean fluorescent intensity/ cell was calculated by corrected total cell fluorescence (CTCF) = Integrated Density – (Area of Selected Cell x Mean Fluorescence of Background readings). Signal intensity in tissue sections were normalized to respective areas. For percentage tolerance of Mtb within hepatocytes, we have calculated the ratio by measuring the mean fluorescent intensity of GFP-Mtb per hepatocyte treated with drug to MFI of GFP-Mtb per hepatocyte treated with DMSO (control). BMDMs were used as the macrophage control. More than 20 fields, each consisting of more than four infected cells have been used for analysis. MFI/ cell was calculated using the Zeiss ZEN blue image analysis software.</p></sec><sec id="s4-3"><title>Tissue immunofluorescence staining</title><sec id="s4-3-1"><title>Paraffin sections</title><p>Five-micron thick sections of paraffin-embedded tissue sections were taken in poly-L-lysine-coated slides (P0425-72EA). Deparaffinization was performed by heating the slides at 50°C for 20 s (three times) till the wax melts, followed by the subsequent steps, 100% xylene (Merck, CAS-1330-20-7) for 10 min (three times), xylene and absolute ethanol (Merck, CAS- 64-17-5) for 10 min, 100% ethanol for 10 min, 70% ethanol for 5 min (two times), 50% ethanol, distilled water for 5 min (2 min) and a final wash in 1x PBS for 5 min (two times). Antigen retrieval was performed in an antigen retrieval buffer (10mM Sodium Citrate, 0.05% Tween-20, pH: 6) by heating the slides at 60°C for 15 min. After antigen retrieval, permeabilization was performed with 0.4% Triton-X 100 in 1X PBS for 20 min followed by proper washing with 1x PBS. Blocking was done with 5% BSA for 1 hr. Sequential addition of primary antibody was performed at 1:100 dilution at 4°C overnight. Primary antibody was washed with 1X PBS followed by counterstaining with DAPI nuclear stain at 1 μg/ml concentration. Mounting was done with a drop of Vectashield (Sigma-Aldrich, F6182-20ml). The slides were visualised in Zeis LSM 980 confocal microscopy at 40X (oil) magnification.</p></sec><sec id="s4-3-2"><title>Cryosections</title><p>Seven-micron thick cryosections were taken in poly-L-Lysine-coated slides (P0425-72EA). The sections were washed with 1X PBS, three times for 5 min each. Permeabilisation was done with 0.25% Triton-X 100 in 1X PBS for 15 min followed by washing with 1X PBS. Blocking was done with 5% BSA for 1 hr followed by incubation with primary antibody overnight at 4°C. After that, the slides were washed with 1X PBS 2 times for 5 min each followed by incubation with fluorophore-conjugated secondary antibody for 45 min. The slides were washed with 1X PBS followed by counterstain with DAPI at 1 μg/ml concentration. Mounting was done with a drop of Vectashield (Sigma-Aldrich, F6182-20 ml). The dilution of the dyes and antibodies used in the staining are mentioned in the table.</p><p>For staining with BODIPY, the sections were incubated with 15 μM of BODIPY for 40 min at room temperature. The slides were visualized in Zeiss LSM 980 confocal microscopy at 40X (oil) magnification.</p></sec></sec><sec id="s4-4"><title>Fluorescence in situ hybridization</title><p>FISH was used to detect Mtb in infected human liver following published protocols (<xref ref-type="bibr" rid="bib61">World Health Organisation, 2023</xref>; <xref ref-type="bibr" rid="bib52">Seung et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Husain et al., 2016</xref>). Briefly, the paraffinized human liver tissue sections were initially deparaffinized using a serial washing step with xylene and ethanol, following which the sections were treated with 1 mg/ml Proteinase K and 10 mg/ml Lysozyme in 10 mM Tris (pH 7.5) at 37°C for 30 min. Next, the samples were incubated in the prehybridization buffer at 37°C for 1 hr. Prehybridization buffer is composed of 20% 2X Saline sodium citrate (SSC), 20% Dextran sulfate, 30% Formamide, 1% 50X Denhardt’s reagent, 2.5% of 10 mg/ml PolyA, 2.5% of 10 mg/ml salmon sperm DNA, 2.5% of 10 mg/ml tRNA. The slides were thoroughly washed with a 2X SSC buffer. The sections were then incubated in hybridization buffer at 95°C for 10 min and then chilled on ice for 10 min. Further hybridization was allowed at 37°C overnight. Hybridization buffer is composed of prehybridization buffer plus 16S Mtb-H<sub>37</sub> Rv probe (5′ FITC – <named-content content-type="sequence">CCACACCGCTAAAG</named-content> – 3′), which is specific for the 16S rRNA of Mtb at a final concentration of 1 ng/μl. The liver tissue sections were next subjected to a series of washing steps with 1 X SSC at room temperature for 1 min, 1 X SSC at 55 °C for 15 min, 1 X SSC at 55 °C for 15 min, 0.5 X SSC at 55 °C for 15 min, 0.5 X SSC at 55 °C for 15 min, 0.5 X SSC at room temperature for 10 min. Coverslips were mounted on glass slides and visualized using Nikon A1R confocal microscope with a 488 nm laser.</p><sec id="s4-4-1"><title>Acid-fast staining and Auramine O and Rhodamine B staining in liver sections</title><p>Acid-fast staining was performed using a ZN Acid Fast Stains-Kit (K005L-1KT, HIMEDIA). Prior to staining, the paraffinized samples were deparaffinized using a serial washing step with xylene and ethanol (1) 100% Xylene for 6 min, (2) Xylene: Ethanol 1:1 for 3 min, (3) 100% Ethanol for 3 min, (4) 95% Ethanol for 3 min, (5) 70% Ethanol for 3 min, (6) 50% Ethanol for 3 min, (7) Distilled water. The glass slides were flooded with Carbol Fuchsin stain and heated to steam for 5 min with a low flame. The glass slides were allowed to stand for 5 min without further heating. The glass slides were then washed in running tap water. The glass slides were decolorized with acid-fast decolorizer for 2 min. (5) Washed with tap water. (6) Counterstain for 30 s with Methylene Blue washed with tap water, dried in air, and examined under 100x objective with oil immersion. The presence or absence of bacteria in infected and uninfected samples was checked through staining with Phenolic Auramine O-Rhodamine B dye (<xref ref-type="bibr" rid="bib22">Eckhardt et al., 2020</xref>) (1/3 dilution of stock solution) (Auramine O-861020-25gm, Sigma) (Rhodamine B-R6626-100gm, Sigma). Coverslips were mounted on glass slides and visualized using CLSM with a 488 nm laser.</p></sec></sec><sec id="s4-5"><title>Bacterial cultures and in vitro experiments</title><p>Virulent laboratory strains of H37Rv, BCG, and GFP-H37Rv bacterial cultures were cultivated on 7H9 medium (BD Difco) supplemented with 10% Oleic Acid-Albumin-Dextrose-Catalase (OADC, BD, Difco), 0.05% glycerol, and 0.05% Tween 80 under shaking at 37°C conditions for in vitro assays. The cultures were then incubated in an orbital shaker at 100 rpm and 37 °C until the mid-log phase. pMN437-GFPm2 vector (Addgene, 32362) was used to electroporate the virulent H37Rv strain to create GFP-H37Rv, which was then maintained in 50 μg/ml hygromycin 7H9-OADC medium. pMSP12: mCherry plasmid (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_30169">Addgene_30169</ext-link>) was electroporated in H37Rv to generate Mtb-H37Rv-mCherry. To prepare the single-cell suspension needed for infection tests, bacterial cultures were passed through a sequence of different gauge needles five times through 23-gauge, 26-gauge, and three times through 30-gauge.</p><p>Human monocytic cell line THP-1 were obtained from American Type Culture Collection (ATCC) and cultured in RPMI-1640 medium with 10% FBS at 37°C and 5% CO2 incubator. THP-1-derived macrophages were obtained by incubating THP-1 cells with 20 ng/ml phorbol 12-myristate 13-acetate (PMA, sigma) for 24 hr followed by washing and maintenance in complete media. The cells were kept in non-PMA-containing complete media for 16-20 hr before infection with Mtb. HepG2, Huh-7, RAW 264.7, and PHCS were grown in DMEM with 10% FBS at 37°C and 5% CO<sub>2</sub> incubator.</p><p>AML-12 cells were cultured in DMEM media containing 1X insulin-transferrin-selenium supplement (ITS-G), under the above-mentioned conditions.</p><p>In vitro and ex vivo infection experiments in primary cells and different cell lines were performed at a multiplicity of infection of 10 (MOI: 10) for both CFU enumeration and confocal microscopy. The macrophage experiments involving THP-1 and RAW 264.7 involved incubating the cells with Mtb-H37Rv for 5-6 hr followed by washing with 1X PBS and amikacin treatment (200 μg/ml for 2 hr) to remove the extracellular bacteria. The cells were kept for the designated time points for 24 hr, 48 hr, and so on and then lysed with lysis buffer (0.05 % SDS in 1X PBS) followed by plating in 7H11 plates.</p><p>For primary mouse hepatocytes and AML-12 cells, the cells were infected with the Mtb at a multiplicity of 10 for 8 hr followed by amikacin treatment (200 μg/ml for 2 r). For HepG2 and Huh-7, the time of incubation was 5- 6 hr followed by washing with 1X PBS and amikacin treatment as previously mentioned to remove the extracellular bacteria.</p><p>HepG2 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0027">CVCL_0027</ext-link>), THP-1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0006">CVCL_0006</ext-link>), AML-12 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0140">CVCL_0140</ext-link>), and RAW 264.7 (CVCL_0493) were obtained from the ATCC (American Type Culture Collection).</p><p>All the cell lines were authenticated by STR (short tandem repeats profiling), and the different cells were periodically checked for mycoplasma contamination with PCR-based methods and DAPI staining. For HepG2, further cell type confirmation was carried out by looking at the expression of the albumin transcript by quantitative real-time PCR and albumin protein expression by confocal microscopy, both of which showed robust levels.</p><p>The percentage drug-tolerant population was calculated using the following formula (A/B X 100) where A is the CFU in the drug-treated group, B is the CFU in the untreated group. The cells were morphologically checked for signs of cell death before proceeding with the plating. For the inhibitor and inducer experiments, the cells were treated with the respective drugs for 48 hr post uptake of Mtb. After that, they were lysed and Mtb CFU was enumerated.</p></sec><sec id="s4-6"><title>Standardization of MOI for PHCs and HepG2</title><p>To standardise the MOI, HepG2 and BMDMs were infected with the following MOI of GFP-Mtb as per the standardized protocol: 1, 2.5, 5, and 10. 6 hr post-infection, the cells were trypsinized and fixed with 2% PFA. The percentage uptake was calculated by flow cytometry. For PHCs, the cells were infected at the above-mentioned MOI and percentage infection was calculated by microscopy as (# of cells with GFP-Mtb/Total # of cells *100).</p></sec><sec id="s4-7"><title>C57BL/6 aerosol challenge</title><p>The mice infection experiments were conducted in the Tuberculosis Aerosol Challenge Facility (TACF, ICGEB, New Delhi, India). C57BL/6 mice were placed in individual ventilated cages within the enclosure, maintaining a temperature of 20–25°C, 30–60% humidity, and 12 hr-12 hr of light-dark cycle. Following the standardized protocol, mice were infected with 200 CFUs of H37Rv in a Wisconsin-Madison chamber. To ensure proper establishment of infection, two animals were euthanized 24 hr post-aerosol challenge. The lungs were harvested and homogenised in 1X PBS and plated in Middlebrook 7H11 agar plates (Difco) supplemented with 10% OADC and 0.5% glycerol. CFU enumeration was done three weeks post-plating.</p></sec><sec id="s4-8"><title>C57BL/6 peritoneal infection</title><p>The mice were injected with 10<sup>6</sup> CFUs of H37Rv in 0.2 ml of 1X PBS. Following infection, on different days post-infection, the lung, spleen, and the liver was harvested and homogenized and plated in Middlebrook 7H11 agar plates (Difco) supplemented with 10% OADC and 0.5% glycerol. CFU enumeration was done three weeks post-plating.</p></sec><sec id="s4-9"><title>List of antibodies and dyes used in the study</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Serial number</th><th align="left" valign="top">Antibodies and dyes</th><th align="left" valign="top">Catalogue number and RRID</th><th align="left" valign="top">Company</th><th align="left" valign="top">Application and dilution</th></tr></thead><tbody><tr><td align="char" char="." valign="top">1.</td><td align="left" valign="top">Rab5</td><td align="left" valign="top">Cat#:2143T, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_823625">AB_823625</ext-link></td><td align="left" valign="top">CST</td><td align="left" valign="top">IF/ICC (1:200)</td></tr><tr><td align="char" char="." valign="top">2.</td><td align="left" valign="top">Rab7</td><td align="left" valign="top">Cat#: 9367T,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB1904103">AB1904103</ext-link></td><td align="left" valign="top">CST</td><td align="left" valign="top">IF/ICC (1:200)</td></tr><tr><td align="char" char="." valign="top">3.</td><td align="left" valign="top">Cathepsin D</td><td align="left" valign="top">Cat#: Ab75852,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_152367">AB_152367</ext-link></td><td align="left" valign="top">Abcam</td><td align="left" valign="top">IF/ICC (1:150)</td></tr><tr><td align="char" char="." valign="top">4.</td><td align="left" valign="top">LAMP1</td><td align="left" valign="top">Cat#: 9091T,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2687579">AB_2687579</ext-link></td><td align="left" valign="top">CST</td><td align="left" valign="top">IF/ICC (1:200)</td></tr><tr><td align="char" char="." valign="top">5.</td><td align="left" valign="top">EEA1</td><td align="left" valign="top">Cat#: 3288T,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2096811">AB_2096811</ext-link></td><td align="left" valign="top">CST</td><td align="left" valign="top">IF/ICC (1:200)</td></tr><tr><td align="char" char="." valign="top">6.</td><td align="left" valign="top">ASPGR1</td><td align="left" valign="top">Cat#:PA5-32030,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2549503">AB_2549503</ext-link></td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">IF/ICC (1:500)</td></tr><tr><td align="char" char="." valign="top">7.</td><td align="left" valign="top">PPAR γ</td><td align="left" valign="top">Cat#:PA3-821A,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2166056">AB_2166056</ext-link></td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">IF/ICC (1:150)<break/>WB (1:1000)</td></tr><tr><td align="char" char="." valign="top">5.</td><td align="left" valign="top">Ag85B</td><td align="left" valign="top">Cat#:Ab43019,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_776575">AB_776575</ext-link></td><td align="left" valign="top">Abcam</td><td align="left" valign="top">IF/ICC (1:800)</td></tr><tr><td align="char" char="." valign="top">6</td><td align="left" valign="top">CD45-APC (clone 104)</td><td align="left" valign="top">Cat#:558702,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_1645215">AB_1645215</ext-link></td><td align="left" valign="top">BD biosciences</td><td align="char" char="." valign="top">1:300</td></tr><tr><td align="char" char="." valign="top">7.</td><td align="left" valign="top">β-actin rabbit polyclonal Antibody.</td><td align="left" valign="top">Cat#:4967 S<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_330288">AB_330288</ext-link></td><td align="left" valign="top">CST</td><td align="left" valign="top">IF/ICC (1:100)<break/>WB (1:2000)</td></tr><tr><td align="char" char="." valign="top">8.</td><td align="left" valign="top">Goat anti-rabbit IgG (H+L) secondary Ab Alexa Fluor 555 Plus</td><td align="left" valign="top">Cat#:A32732,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:2633281">2633281</ext-link></td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">IF/ICC (1:400)</td></tr><tr><td align="char" char="." valign="top">9.</td><td align="left" valign="top">Goat anti-rabbit IgG (H+L) Secondary Antibody, Alexa Fluor 488</td><td align="left" valign="top">Cat#:A11008,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_143165">AB_143165</ext-link></td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">IF/ICC (1:400)</td></tr><tr><td align="char" char="." valign="top">10.</td><td align="left" valign="top">Goat anti-rabbit IgG (H+L) Secondary Antibody, Alexa Fluor 405</td><td align="left" valign="top">Cat#:A-31556,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_221605">AB_221605</ext-link></td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">IF/ICC (1:400)</td></tr><tr><td align="char" char="." valign="top">11</td><td align="left" valign="top">Anti-Albumin antibody</td><td align="left" valign="top">Cat#:PA5-143811<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3075025">AB_3075025</ext-link></td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">IF/ICC (1:250)</td></tr><tr><td align="char" char="." valign="top">12</td><td align="left" valign="top">Chicken anti-rabbit IgG (H+L) Secondary antibody Alexa Fluor 647</td><td align="left" valign="top">Cat#:A-21443<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2565861">AB_2565861</ext-link></td><td align="left" valign="top"/><td align="left" valign="top">IF/ICC (1:1000)</td></tr><tr><td align="char" char="." valign="top">13.</td><td align="left" valign="top">Lysotracker Red</td><td align="left" valign="top">L7528</td><td align="left" valign="top">Invitrogen</td><td align="char" char="." valign="top">500 nM</td></tr><tr><td align="char" char="." valign="top">14.</td><td align="left" valign="top">BODIPY-493/503</td><td align="left" valign="top">D3922</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Staining (10–15 µM)</td></tr><tr><td align="char" char="." valign="top">15.</td><td align="left" valign="top">BODIPY 558/568 C12</td><td align="left" valign="top">D3835</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Metabolic Labeling (7.5 µg/ml)</td></tr><tr><td align="char" char="." valign="top">16.</td><td align="left" valign="top">Phalloidin-Alexa Fluor 488</td><td align="left" valign="top">A12379</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">IF/ICC<break/>1 unit/slide</td></tr><tr><td align="char" char="." valign="top">17.</td><td align="left" valign="top">Phalloidin-Alexa Fluor 555 plus</td><td align="left" valign="top">A30106</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">IF/ICC<break/>1 unit/slide</td></tr><tr><td align="char" char="." valign="top">18.</td><td align="left" valign="top">HCS LipidTOX Red Neutral Lipid Stain</td><td align="left" valign="top">H34476</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">IF/ICC (1:400)</td></tr><tr><td align="char" char="." valign="top">17.</td><td align="left" valign="top">DAPI</td><td align="left" valign="top">D9542</td><td align="left" valign="top">Sigma-Aldrich</td><td align="char" char="." valign="top">1 ug/ml</td></tr><tr><td align="char" char="." valign="top">18.</td><td align="left" valign="top">ZN Acid Fast Stains</td><td align="left" valign="top">K005L-1KT</td><td align="left" valign="top">Himedia</td><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">19.</td><td align="left" valign="top">Auramine O</td><td align="char" char="ndash" valign="top">861020–25 gm</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">19</td><td align="left" valign="top">Rhodamine B</td><td align="left" valign="top">R6626-100gm</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top"/></tr></tbody></table></table-wrap></sec><sec id="s4-10"><title>List of reagents in the study</title><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Serial no</th><th align="left" valign="top">Reagents</th><th align="left" valign="top">Catalogue number</th></tr></thead><tbody><tr><td align="left" valign="top">1.</td><td align="left" valign="top">C75</td><td align="left" valign="top">C5490-5MG, Sigma-Aldrich</td></tr><tr><td align="left" valign="top">2.</td><td align="left" valign="top">OA-BSA</td><td align="left" valign="top">O3008-5ML<bold>,</bold> Sigma-Aldrich</td></tr><tr><td align="left" valign="top">5.</td><td align="left" valign="top">GW9662</td><td align="left" valign="top">M6191-25MG, Sigma-Aldrich</td></tr><tr><td align="left" valign="top">6.</td><td align="left" valign="top">Rosiglitazone</td><td align="left" valign="top">R2408-10MG, Sigma-Aldrich</td></tr><tr><td align="left" valign="top">7.</td><td align="left" valign="top">T863</td><td align="left" valign="top">SML0539-5MG, Sigma-Aldrich</td></tr><tr><td align="left" valign="top">8.</td><td align="left" valign="top">Rifampicin</td><td align="char" char="ndash" valign="top">557303–1 G, Merck</td></tr><tr><td align="left" valign="top">9.</td><td align="left" valign="top">Isoniazid</td><td align="left" valign="top">I3377-5G, Merck</td></tr><tr><td align="left" valign="top">10.</td><td align="left" valign="top">PMA (Phorbol 12-myristate 13-acetate)</td><td align="left" valign="top">P8139-1MG, Merck</td></tr><tr><td align="left" valign="top">11.</td><td align="left" valign="top">Mouse MCSF (macrophage colony-stimulating factor)</td><td align="left" valign="top">130-101-706 (25 µg), Miltenyi Biotec</td></tr><tr><td align="left" valign="top">12.</td><td align="left" valign="top">Insulin-Transferrin-Selenium (ITS -G) (100 X)</td><td align="char" char="." valign="top">41400045, Gibco</td></tr></tbody></table></table-wrap></sec><sec id="s4-11"><title>Sorting of labeled H37Rv cells</title><p>The infected hepatocytes were trypsinized and washed with 1X PBS followed by passing through 40 µm cell strainer to make single cell suspension. After that, the cells positive for mCherry signals were sorted using the BD FACS Aria at TACF, ICGEB. Approximately 1 million cells were used for RNA isolation per sample.</p></sec><sec id="s4-12"><title>Primary hepatocyte isolation</title><p>After euthanizing the mice, the peritoneal cavity was opened, and the liver was perfused with 1X HBSS solution till exsanguination was complete. After that collagenase solution (17 mg in 30 ml of 1X HBSS) was passed for digestion. The liver was cut into small pieces and kept in 25 ml of DMEM media followed by lysing the tissues with a glass pestle and sieve. The cells were then passed through a 70 µM cell strainer. 25 ml of Percoll was added to the cells with proper mixing. It was centrifuged at 1000 rpm for 5 min. The floating cells were removed, and a brownish layer of pure hepatocytes was pelleted at the bottom. The cells were counted and plated according to the experimental need on a collagen-coated plate.</p></sec><sec id="s4-13"><title>Isolation of BMDMs from mouse</title><p>BMDMs used for Mtb infection studies were isolated following the published protocol with minor modifications (<xref ref-type="bibr" rid="bib56">Toda, 2021</xref>). Briefly, the epiphysis of the femurs and tibia from C57BL/6 mice were cut and the bone marrow were gently flushed into BMDM supplemented with 10% FBS and 1% penicillin streptomycin. The bone marrow cells were centrifuged at 200 X g for 5 min at 4°C. The cell pellet was aspirated with 1X PBS and treated with RBC Lysis buffer for 3 min on ice, followed by the addition of complete media. The cells were resuspended in 5 ml of the media and passed through a 70 μm cell strainer. The cells were seeded in complete DMEM supplemented with 10 ng/ml of MCSF. On the third day, half of the media volume was replaced by fresh DMEM supplemented with 10ng/ml of MCSF. On the seventh day, the cells were trypsinized, counted, and seeded according to experimental requirements.</p></sec><sec id="s4-14"><title>Lipid extraction protocol and mass spectrometry</title><p>Five million HepG2 cells were infected with Mtb-H37Rv at MOI 10 and kept for 24 hr and 48 hr post-infection. An equal number of uninfected cells were taken. The cells were scrapped, and the procedure of Bligh and Dyer was followed <xref ref-type="bibr" rid="bib9">Bligh and Dyer, 1959</xref>. In brief, the cells were lysed in 1% Triton X-100 after being rinsed twice with 1X PBS. Following lysis, the lysate was vortexed and four volumes of methanol-chloroform (2:1) were added. After that, one volume each of water, chloroform, and 50 mM citric acid was added and vortexed. Following a 10-min centrifugation at 10,000 rpm at 4°C, the lower organic phase was collected and dried using liquid nitrogen. All semi-quantitative lipid measurements were done using previously reported high-resolution MS/MS methods and chromatographic techniques on an Agilent 6545 QTOF instrument. All sterols were resolved using a Gemini 5U C-18 column (Phenomenex) while DAGs/TAGs were resolved using a Luna 5U C-5 column (Phenomenex) using established solvent systems.</p></sec><sec id="s4-15"><title>Cell lysate preparation and Western blotting</title><p>The cells were washed twice with 1X PBS followed by lysis with SDS-RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton-X 100, 1 mM DTT, 1X Proteinase inhibitor). The cells were incubated with the buffer for 30 min in ice followed by vortexing for 5 min. The supernatant fraction was collected by centrifuging at 10,000 rpm for 20 min at 4°C. The protein concentration was determined by bicinchoninic acid (BCA) protein estimation kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA, 23227) following the manufacturer’s protocol. 60-80 ug of protein was resolved in SDS-PAGE followed by transferring onto a PVDF membrane. Blocking was done in 5% skimmed milk in 1X TBST followed by incubation with primary antibodies overnight at 4°C. The membranes were washed three times with 1x TBST for 10 min each followed by incubation with the HRP-conjugated secondary antibody for 1 hr. Immobilon HRP substrate was used to develop the blots and ImageQuant Chemiluminescent imaging system (LAS 500) (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link>) was used to acquire the images. Band intensities were measured by using ImageJ (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_003070">SCR_003070</ext-link>).</p></sec><sec id="s4-16"><title>MIC determination of Mtb isolated from primary hepatocytes and primary hepatocytes treated with rifampicin and isoniazid</title><p>Mtb was isolated from primary hepatocytes, primary hepatocytes treated with 0.5 μg/ml of rifampicin and primary hepatocytes treated with 0.5 μg/ml of isoniazid. These bacteria were grown to a logarithmic phase of OD<sub>600</sub> = 0.6 in Middlebrook 7H9 broth supplemented with 10% OADC, 0.05% glycerol, and 0.05% Tween 80 under shaking conditions. Single-cell suspension of the Mtb was made as previously described. Twofold serial dilutions of both rifampicin and isoniazid was prepared in 0.1 ml 7H9-OADC (without Tween 80) (The concentration and the dilution of the drugs have been mentioned in the figure) in 96-well flat bottom microplates. Approximately 5×10<sup>4</sup> Mtb cells were added to each well in a volume of 0.1 ml. Control wells containing (Mtb only, medium + inhibitor, and only medium) were included in the plate setup. The plate was incubated at 37°C 5 days, followed by the addition of 20 μl of 0.02% resazurin for 24 hr. Visually, minimum inhibitory concentration (MIC) was noted as the lowest drug concentration that prevented the change of color from blue to pink.</p></sec><sec id="s4-17"><title>qRT-PCR of intracellular Mtb isolated from hepatocytes</title><p>HepG2 cells were infected with Mtb at a MOI of 10 and at the respective time points post-infection, the intracellular Mtb was isolated. In all experiments, the cells were treated with amikacin to remove the extracellular bacteria, followed by subsequent washing by 1X PBS. 4M Guanidine isocyanate was added to the flasks in equal amount to the media and the cells were scraped. The suspension was centrifuged at 3500 rpm for 7 min and the pellet was resuspended in 350 μl of the RNA Lysis buffer of MN Kit (740955.250), followed by bead beating. RNA was isolated as per the manufacturer’s protocol. Isolated RNA was treated with Dnase (PGM052, Puregene) for 1 hr to remove genomic DNA contamination. RNA integrity was checked by running it on a 2% agarose gel with RNA loading dye.</p><p>1 μg of RNA was reverse transcribed to cDNA using the Takara cDNA synthesis kit (6110A) as per the manufacturer’s protocol. Gene expression analysis by quantitative real-time PCR was performed PowerUp SYBR Green PCR Thermo Fischer Scientific, (A25742) master mix in ABI 7500 FAST instrument. 16S rRNA was used as the normalizing control and comparative Ct method was used for quantification.</p></sec><sec id="s4-18"><title>Fluorescent fatty acid labeling of HepG2 and isolation</title><p>HepG2 cells were incubated with 7.5 μg/ml of fluorescently tagged fatty acid (BODIPY 558/568 C<sub>12</sub>) for 24 hr. The unincorporated fatty acids were removed by washing it with 1X PBS, three times. After that, the cells were treated with DMSO or inhibitors (T863 and C75) for 24 hr, followed by infection with Mtb at a MOI of 10, following the standardized protocol of infection. A separate set of cells before infection were analysed for the effect of the inhibitors on LD formation by microscopy.</p><p>After, 48 hr post-infection, the cells were washed with 1X PBS and treated with Triton X –100 (0.05% v/v in water), probe sonicated, and Mtb from the cells were isolated by centrifuging at 3500 RPM for 8 min. Isolated Mtb cells were washed with 1X PBS and fixed with 4% PFA and stained with DAPI (1 mg/ml). The cells were mounted on poly-L-lysine-coated slides with an antifade agent. The cells were visualised in Zeiss 980 LSM confocal microscope at 100X, magnification.</p></sec><sec id="s4-19"><title>Gene expression studies</title><sec id="s4-19-1"><title>RNA isolation</title><p>Total RNA was isolated from HepG2, PHCs, and liver sections using the MN-NucleoSpin RNA isolation kit (740955.250) following the manufacturer’s protocol. For RNA sequencing, an equal number of cells was used during isolation. For liver tissue, approximately 10 mg was tissue was used. The quality of the RNA was verified by running it on a 1.5% agarose gel and by monitoring 260/280 ratios. All the RNA samples were frozen together in –80°C. For RNA sequencing, 3-5 μg of RNA was shipped in sodium acetate buffer (3 M Sodium acetate, pH 5.2) with 100% Ethanol. Four biological replicates from each time point were sent for sequencing. The RNA samples with RNA integrity number (RIN &gt; 8.5) were used for library preparation.</p><p>RNA samples (for four biological replicates) were subjected to pair-end RNA sequencing after rRNA depletion on the Illumina platform Novaseq-6000 at CCMB, Hyderabad, India. Quality control and sequence trimming was performed using fastp (v0.23.2) (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_016962">SCR_016962</ext-link>). The trimmed paired-end reads were aligned to the human genome (GRCh38) using the HISAT2 (v2.2.1) (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_015530">SCR_015530</ext-link>) pipeline. Reads were assembled into transcripts using StringTie (v2.2.1) (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_016323">SCR_016323</ext-link>). Annotation was conducted using aligned sequences and a GTF annotation file. The mapped reads were then used for generating the count table using StringTie (v2.2.1), genes lacking an Ensembl ID annotation were excluded. We arrived at a list of 62694 genes which were used for further analysis (available through GEO accession- GSE256184). The differential count was performed by DEseq2 (R package) using the uninfected samples of respective time points. Pathway enrichment was performed using the GO database and clusters were visualized using the R package ClusterProfiler. Further pathways of interest were analyzed by GAGE and visualized using Pathview (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002732">SCR_002732</ext-link>) in KEGG view.</p></sec><sec id="s4-19-2"><title>cDNA synthesis and RT-qPCR</title><p>1 μg of RNA was reverse transcribed to cDNA using the Takara cDNA synthesis kit (6110A) as per the manufacturer’s protocol. Gene expression analysis by quantitative real-time PCR was performed PowerUp SYBR Green PCR Thermo Fischer Scientific, (A25742) master mix in ABI 7500 FAST instrument. Beta-actin was used as the normalizing control and comparative Ct method was used for quantification.</p></sec><sec id="s4-19-3"><title>List of primers used in the study</title><table-wrap id="inlinetable3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">GENE NAMES</th><th align="left" valign="top">FORWARD PRIMER (5<bold>'</bold>-------------<bold>&gt;3'</bold>)</th><th align="left" valign="top">REVERSE PRIMER (5<bold>'</bold>-------------<bold>&gt;3'</bold>)</th><th align="left" valign="top"/></tr></thead><tbody><tr><td align="left" valign="top">β-actin</td><td align="left" valign="top"><named-content content-type="sequence">ATGGAGGGGAATACAGCCC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">TTCTTTGCAGCTCCTTCGTT</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">ppar-γ</td><td align="left" valign="top"><named-content content-type="sequence">CTCTGGGAGATTCTCCTGTTGA</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GGTGGGCCAGAATGGCATCT</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">ppar-α</td><td align="left" valign="top"><named-content content-type="sequence">AGAGCCCCATCTGTCCTCTC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">ACTGGTAGTCTGCAAAACCAAA</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">fasn</td><td align="left" valign="top"><named-content content-type="sequence">CTGCGTGGCTATGATTATGG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">AGGTTGCTGTCGTCTGTAGT</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">acat1</td><td align="left" valign="top"><named-content content-type="sequence">CAGGAAGTAAGATGCCTGGAAC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">TTCACCCCCTTGGATGACATT</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">acat2</td><td align="left" valign="top"><named-content content-type="sequence">CCCGTGGTCATCGTCTCAG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GGACAGGGCACCATTGAAGG</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">dgat1</td><td align="left" valign="top"><named-content content-type="sequence">TGCCCTGACAGAGCAGATGG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CAGGTTGACATCCCGGTAGG</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">dgat2</td><td align="left" valign="top"><named-content content-type="sequence">TGGCGCTACTTCCGAGACTAC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">TGCTGACTTCAGTAGCCTCTGTG</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">nat2</td><td align="left" valign="top"><named-content content-type="sequence">ACACTCCAGCCAATAAGTACAGC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GGTAGGAACGTCCAAACCCA</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">Slco1b2</td><td align="left" valign="top"><named-content content-type="sequence">GGGAACATGCTTCGTGGGATA</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GGAGTTATGCGGACACTTCTC</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">aadac</td><td align="left" valign="top"><named-content content-type="sequence">TACCGCTTCCAGATGCTATTGA</named-content></td><td align="left" valign="top"><named-content content-type="sequence">ACTGATTCCCAAAAGTTCACCAA</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">cyp2e1</td><td align="left" valign="top"><named-content content-type="sequence">CATCACCGTTGCCTTGCTTG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GGGGCAGGTTCCAACTTCT</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">ces1c</td><td align="left" valign="top"><named-content content-type="sequence">GCACTACGCTGGGTCCAAGAT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">AAAGATGGTCACGGAATCCG</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">ces2c</td><td align="left" valign="top"><named-content content-type="sequence">GCTGAATGCTGGGTTCTTCG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GCTGCCTTGGATCTGTCCTGT</named-content></td><td align="left" valign="top">Mouse</td></tr><tr><td align="left" valign="top">β-actin</td><td align="left" valign="top"><named-content content-type="sequence">AAGGCCAACCGCGAGAAGAT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GCCAGAGGCGTACAGGGATA</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">pparγ</td><td align="left" valign="top"><named-content content-type="sequence">GGTGAAACTCTGGGAGATTCT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CTCTGTGTCAACCATGGTCA</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">fasn</td><td align="left" valign="top"><named-content content-type="sequence">AGTACACACCCAAGGCCAAG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GTGGATGATGCTGATGATGG</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">acat1</td><td align="left" valign="top"><named-content content-type="sequence">TACCAGAAGTAAAGCAGCATGG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">TCATTCAGTGTACTGGCATTGG</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">acat2</td><td align="left" valign="top"><named-content content-type="sequence">CTTTAGCACGGATAGTTTCCTGG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GCTGCAAAGGCTTCATTGATTTC</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">dgat1</td><td align="left" valign="top"><named-content content-type="sequence">CAATCTGACCTACCGCGATCT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">TCGATGATGCGTGAGTAGTCC</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">dgat2</td><td align="left" valign="top"><named-content content-type="sequence">GAATGGGAGTGGCAATGCTAT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CCTCGAAGATCACCTGCTTGT</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">nat2</td><td align="left" valign="top"><named-content content-type="sequence">CCAGAAGGGGTTTACTGTTTGG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CAGGTTTGGGCACGAGATTTC</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">mgat1</td><td align="left" valign="top"><named-content content-type="sequence">CGCAAGTTCCAGGGCTACTAC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CTTCAGCAGCGGATAGGTGG</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">fsp27</td><td align="left" valign="top"><named-content content-type="sequence">ATGGACTACGCCATGAAGTCT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGGTGCTAACACGACAGGG</named-content></td><td align="left" valign="top">Human</td></tr><tr><td align="left" valign="top">Rv1258c</td><td align="left" valign="top"><named-content content-type="sequence">CTACGAGGCGATCCTCAACC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGAGGATGGACAACCCGAAT</named-content></td><td align="left" valign="top">Mtb</td></tr><tr><td align="left" valign="top">Rv1819c</td><td align="left" valign="top"><named-content content-type="sequence">ATCGGGGTTTTCAGCGTGAT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GTCGAGCCAGTCTTGTGTGA</named-content></td><td align="left" valign="top">Mtb</td></tr><tr><td align="left" valign="top">Rv1218c</td><td align="left" valign="top"><named-content content-type="sequence">ATCGAGATTCGCGGACTGAC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">ACATCGCCTGGAACATAGGC</named-content></td><td align="left" valign="top">Mtb</td></tr><tr><td align="left" valign="top">Rv1410c</td><td align="left" valign="top"><named-content content-type="sequence">ATGGTGACGCTGGTTGATGT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGGTAGGGCGATAAGGAACC</named-content></td><td align="left" valign="top">Mtb</td></tr><tr><td align="left" valign="top">tgs1 (Rv3130c)</td><td align="left" valign="top"><named-content content-type="sequence">CCTTCTTATCGTCGCTCGCT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GCCAAGATCGAAGTCGGGAT</named-content></td><td align="left" valign="top">Mtb</td></tr><tr><td align="left" valign="top">tgs4 (Rv3088)</td><td align="left" valign="top"><named-content content-type="sequence">ACGGTCTCGTTCCTCAACAC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CCGGTGAATCGGAGAGGAAG</named-content></td><td align="left" valign="top">Mtb</td></tr><tr><td align="left" valign="top">lipY (Rv3097c)</td><td align="left" valign="top"><named-content content-type="sequence">TCTGCGCTCGAAACTCACTT</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GCTCATCCCGTCATAGGTGG</named-content></td><td align="left" valign="top">Mtb</td></tr><tr><td align="left" valign="top">acrA1 (Rv3391)</td><td align="left" valign="top"><named-content content-type="sequence">ATGGCGGTCAACTACTTCGG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CCTTGGTGGGCAGATACGAG</named-content></td><td align="left" valign="top">Mtb</td></tr></tbody></table></table-wrap></sec><sec id="s4-19-4"><title>List of reagents in the study</title><table-wrap id="inlinetable4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent</th><th align="left" valign="top">Company</th><th align="left" valign="top">Catalogue number</th></tr></thead><tbody><tr><td align="left" valign="top">Immobilon Forte Western HRP substrate</td><td align="left" valign="top">Millipore</td><td align="left" valign="top">WBLUF0500</td></tr><tr><td align="left" valign="top">Amersham Hybond Western blotting membranes, PVDF</td><td align="left" valign="top">Merck</td><td align="left" valign="top">GE10600023</td></tr><tr><td align="left" valign="top">PowerUP SYBR</td><td align="left" valign="top">Thermo Fischer Scientific</td><td align="left" valign="top">A25742</td></tr><tr><td align="left" valign="top">Vectashield</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">F6182</td></tr><tr><td align="left" valign="top">Primescript 1<sup>st</sup> strand cDNA synthesis kit</td><td align="left" valign="top">Takara Bio</td><td align="char" char="." valign="top">6110 A</td></tr><tr><td align="left" valign="top">NucleoSpin RNA isolation Kit</td><td align="left" valign="top">Macherey-Nagel</td><td align="char" char="." valign="top">74106</td></tr><tr><td align="left" valign="top">ProLong Gold antifade reagent</td><td align="left" valign="top">Thermo Fischer Scientific</td><td align="left" valign="top">P36930</td></tr><tr><td align="left" valign="top">PolyFreeze Tissue Freezing medium</td><td align="left" valign="top">Sigma- Aldrich</td><td align="left" valign="top">SHH0026</td></tr><tr><td align="left" valign="top">Microscope slides</td><td align="left" valign="top">Himedia</td><td align="left" valign="top">BG005</td></tr><tr><td align="left" valign="top">Poly-Prep slides</td><td align="left" valign="top">Sigma- Aldrich</td><td align="left" valign="top">P0425-72EA</td></tr><tr><td align="left" valign="top">2 X RNA loading dye</td><td align="left" valign="top">Thermo Scientific</td><td align="left" valign="top">R0641</td></tr></tbody></table></table-wrap></sec><sec id="s4-19-5"><title>Softwares</title><p>All the graphs have been generated using GraphPad Prism 10 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/">http://www.graphpad.com/</ext-link>) and Microsoft Excel (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_016137">SCR_016137</ext-link>). The schematics have been drawn with the help of <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">Biorender.com</ext-link> (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_018361">SCR_018361</ext-link>).</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Software, Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Resources, Supervision, Validation, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con10"><p>Resources, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con11"><p>Supervision, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Resources, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing – original draft, Project administration</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Paraffinized non-Mtb-infected, and Mtb-infected human autopsied liver specimens were obtained from the Postgraduate Institute of Medical Education and Research, Chandigarh, India. The Institutional Ethics Committee of CSIR-IMTech (Council of Scientific and Industrial Research-Institute of Microbial Technology) approved all research experiments involving human samples (Approval no [IEC (May 2021) #6]). The samples utilized in the study are from a library of autopsied human specimens in PGIMER (Postgraduate Institute of Medical Education and Research). The consent is provided by the relatives of the deceased person while its submission to the PGIMER. The details of the human subjects have been provided in the Supplementary file 1.</p></fn><fn fn-type="other"><p>All the mice (C57BL/6) were housed in the animal house at the National Institute of Immunology (NII) before being transported to the TACF-ICGEB (Tuberculosis AerosolChallenge Facility), for subsequent animal infection studies. The animal experiments were performed adhering to the institutional guidelines (Approval number: Institutional Animal Ethical Committee, IAEC 543/20). Female Hartley Dunkin guinea pigs were used for infection studies in TACF-ICGEB in accordance with the institutional guidelines (Approval number: Institutional Animal Ethical Committee, IEAC #440/17).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-103817-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Details of the human biopsy samples used in the study.</title></caption><media xlink:href="elife-103817-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Differentially expressed genes between uninfected and Mtb-infected HepG2 at 0 hr and 48 hr post-infection.</title></caption><media xlink:href="elife-103817-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files; source data files have been provided for all figures. RNA sequencing data were deposited in GEO with the accession number GSE256184.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Gokhale</surname><given-names>R</given-names></name><name><surname>Mohanty</surname><given-names>D</given-names></name><name><surname>Nandicoori</surname><given-names>VK</given-names></name><name><surname>Sarkar</surname><given-names>B</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Transciptomic changes in <italic>Mycobacterium tuberculosis</italic> (Mtb) infected hepatocytes at early and late time points of infection</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE256184">GSE256184</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Lakshyaveer Singh, Tuberculosis Aerosol Challenge Facility (TACF), ICGEB for mice experiments. We thank Dr. Neerja Wadhwa for helping in the NII Central Confocal facility, Mr. Birendra Nath Roy for the preparation of the cryosections, and the NII animal facility for providing us with the animals. We thank the Next Generation Sequencing (NGS) facility at CSIR-CCMB for transcriptomic support.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S-Q</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine</article-title><source>Genomics, Proteomics &amp; Bioinformatics</source><volume>14</volume><fpage>298</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.gpb.2016.03.008</pub-id><pub-id pub-id-type="pmid">27729266</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almazroo</surname><given-names>OA</given-names></name><name><surname>Miah</surname><given-names>MK</given-names></name><name><surname>Venkataramanan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Drug metabolism in the liver</article-title><source>Clinics in Liver Disease</source><volume>21</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2016.08.001</pub-id><pub-id pub-id-type="pmid">27842765</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alper</surname><given-names>CA</given-names></name><name><surname>Johnson</surname><given-names>AM</given-names></name><name><surname>Birtch</surname><given-names>AG</given-names></name><name><surname>Moore</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>Human C’3: evidence for the liver as the primary site of synthesis</article-title><source>Science</source><volume>163</volume><fpage>286</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1126/science.163.3864.286</pub-id><pub-id pub-id-type="pmid">4883617</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>E</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name><name><surname>Woodyard</surname><given-names>KC</given-names></name><name><surname>Montoya</surname><given-names>MJ</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Hoang</surname><given-names>KV</given-names></name><name><surname>Hayhurst</surname><given-names>A</given-names></name><name><surname>Azad</surname><given-names>AK</given-names></name><name><surname>Schlesinger</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>PPARγ is critical for <italic>Mycobacterium tuberculosis</italic> induction of Mcl-1 and limitation of human macrophage apoptosis</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1007100</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007100</pub-id><pub-id pub-id-type="pmid">29928066</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barreto</surname><given-names>EA</given-names></name><name><surname>Cruz</surname><given-names>AS</given-names></name><name><surname>Veras</surname><given-names>FP</given-names></name><name><surname>Martins</surname><given-names>R</given-names></name><name><surname>Bernardelli</surname><given-names>RS</given-names></name><name><surname>Paiva</surname><given-names>IM</given-names></name><name><surname>Lima</surname><given-names>TM</given-names></name><name><surname>Singh</surname><given-names>Y</given-names></name><name><surname>Guimarães</surname><given-names>RC</given-names></name><name><surname>Damasceno</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>N</given-names></name><name><surname>Alves</surname><given-names>JM</given-names></name><name><surname>Gonçalves</surname><given-names>TT</given-names></name><name><surname>Forato</surname><given-names>J</given-names></name><name><surname>Muraro</surname><given-names>SP</given-names></name><name><surname>Souza</surname><given-names>GF</given-names></name><name><surname>Batah</surname><given-names>SS</given-names></name><name><surname>Proenca-Modena</surname><given-names>JL</given-names></name><name><surname>Mori</surname><given-names>MA</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name><name><surname>Louzada-Junior</surname><given-names>P</given-names></name><name><surname>Cunha</surname><given-names>TM</given-names></name><name><surname>Nakaya</surname><given-names>HI</given-names></name><name><surname>Fabro</surname><given-names>A</given-names></name><name><surname>de Oliveira</surname><given-names>RDR</given-names></name><name><surname>Arruda</surname><given-names>E</given-names></name><name><surname>Réa</surname><given-names>R</given-names></name><name><surname>Réa Neto</surname><given-names>Á</given-names></name><name><surname>Fernandes da Silva</surname><given-names>MM</given-names></name><name><surname>Leiria</surname><given-names>LO</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>COVID-19-related hyperglycemia is associated with infection of hepatocytes and stimulation of gluconeogenesis</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2217119120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2217119120</pub-id><pub-id pub-id-type="pmid">37186819</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bechmann</surname><given-names>LP</given-names></name><name><surname>Hannivoort</surname><given-names>RA</given-names></name><name><surname>Gerken</surname><given-names>G</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name><name><surname>Canbay</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The interaction of hepatic lipid and glucose metabolism in liver diseases</article-title><source>Journal of Hepatology</source><volume>56</volume><fpage>952</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.08.025</pub-id><pub-id pub-id-type="pmid">22173168</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigier-Bompadre</surname><given-names>M</given-names></name><name><surname>Montagna</surname><given-names>GN</given-names></name><name><surname>Kühl</surname><given-names>AA</given-names></name><name><surname>Lozza</surname><given-names>L</given-names></name><name><surname>Kupz</surname><given-names>A</given-names></name><name><surname>Vogelzang</surname><given-names>A</given-names></name><name><surname>Mollenkopf</surname><given-names>HJ</given-names></name><name><surname>Löwe</surname><given-names>D</given-names></name><name><surname>Bandermann</surname><given-names>S</given-names></name><name><surname>Dorhoi</surname><given-names>A</given-names></name><name><surname>Brinkmann</surname><given-names>V</given-names></name><name><surname>Matuschewski</surname><given-names>K</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Mycobacterium tuberculosis</italic> infection modulates adipose tissue biology</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006676</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006676</pub-id><pub-id pub-id-type="pmid">29040326</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisht</surname><given-names>MK</given-names></name><name><surname>Dahiya</surname><given-names>P</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The cause-effect relation of tuberculosis on incidence of diabetes mellitus</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>13</volume><elocation-id>1134036</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1134036</pub-id><pub-id pub-id-type="pmid">37434784</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bligh</surname><given-names>EG</given-names></name><name><surname>Dyer</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="1959">1959</year><article-title>A rapid method of total lipid extraction and purification</article-title><source>Canadian Journal of Biochemistry and Physiology</source><volume>37</volume><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1139/o59-099</pub-id><pub-id pub-id-type="pmid">13671378</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussi</surname><given-names>C</given-names></name><name><surname>Gutierrez</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>Mycobacterium tuberculosis</italic> infection of host cells in space and time</article-title><source>FEMS Microbiology Reviews</source><volume>43</volume><fpage>341</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuz006</pub-id><pub-id pub-id-type="pmid">30916769</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celton-Morizur</surname><given-names>S</given-names></name><name><surname>Merlen</surname><given-names>G</given-names></name><name><surname>Couton</surname><given-names>D</given-names></name><name><surname>Desdouets</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Polyploidy and liver proliferation: central role of insulin signaling</article-title><source>Cell Cycle</source><volume>9</volume><fpage>460</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.4161/cc.9.3.10542</pub-id><pub-id pub-id-type="pmid">20090410</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>SW</given-names></name><name><surname>Pan</surname><given-names>WS</given-names></name><name><surname>Lozano Beltran</surname><given-names>D</given-names></name><name><surname>Oleyda Baldelomar</surname><given-names>L</given-names></name><name><surname>Solano</surname><given-names>MA</given-names></name><name><surname>Tuero</surname><given-names>I</given-names></name><name><surname>Friedland</surname><given-names>JS</given-names></name><name><surname>Torrico</surname><given-names>F</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gut hormones, appetite suppression and cachexia in patients with pulmonary TB</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e54564</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0054564</pub-id><pub-id pub-id-type="pmid">23358528</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>L</given-names></name><name><surname>Theron</surname><given-names>G</given-names></name><name><surname>Wood</surname><given-names>R</given-names></name><name><surname>Marais</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title><italic>Mycobacterium tuberculosis</italic> transmission in high-incidence settings-new paradigms and insights</article-title><source>Pathogens</source><volume>11</volume><elocation-id>1228</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11111228</pub-id><pub-id pub-id-type="pmid">36364978</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosma</surname><given-names>CL</given-names></name><name><surname>Sherman</surname><given-names>DR</given-names></name><name><surname>Ramakrishnan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The secret lives of the pathogenic mycobacteria</article-title><source>Annual Review of Microbiology</source><volume>57</volume><fpage>641</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1146/annurev.micro.57.030502.091033</pub-id><pub-id pub-id-type="pmid">14527294</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>D</given-names></name><name><surname>Jamwal</surname><given-names>S</given-names></name><name><surname>Jyoti</surname><given-names>N</given-names></name><name><surname>Patnaik</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Actionable mechanisms of drug tolerance and resistance in <italic>Mycobacterium tuberculosis</italic></article-title><source>The FEBS Journal</source><volume>291</volume><fpage>4433</fpage><lpage>4452</lpage><pub-id pub-id-type="doi">10.1111/febs.17142</pub-id><pub-id pub-id-type="pmid">38676952</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>HE</given-names></name><name><surname>McCorkell</surname><given-names>L</given-names></name><name><surname>Vogel</surname><given-names>JM</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Long COVID: major findings, mechanisms and recommendations</article-title><source>Nature Reviews. Microbiology</source><volume>21</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmid">36639608</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>NJ</given-names></name><name><surname>Santucci</surname><given-names>P</given-names></name><name><surname>Gutierrez</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Host cell environments and antibiotic efficacy in tuberculosis</article-title><source>Trends in Microbiology</source><volume>32</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2023.08.009</pub-id><pub-id pub-id-type="pmid">37709598</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deb</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>C-M</given-names></name><name><surname>Dubey</surname><given-names>VS</given-names></name><name><surname>Daniel</surname><given-names>J</given-names></name><name><surname>Abomoelak</surname><given-names>B</given-names></name><name><surname>Sirakova</surname><given-names>TD</given-names></name><name><surname>Pawar</surname><given-names>S</given-names></name><name><surname>Rogers</surname><given-names>L</given-names></name><name><surname>Kolattukudy</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A novel in vitro multiple-stress dormancy model for <italic>Mycobacterium tuberculosis</italic> generates a lipid-loaded, drug-tolerant, dormant pathogen</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e6077</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006077</pub-id><pub-id pub-id-type="pmid">19562030</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dharmalingam</surname><given-names>M</given-names></name><name><surname>Yamasandhi</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nonalcoholic fatty liver disease and type 2 diabetes mellitus</article-title><source>Indian Journal of Endocrinology and Metabolism</source><volume>22</volume><fpage>421</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.4103/ijem.IJEM_585_17</pub-id><pub-id pub-id-type="pmid">30090738</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Díaz</surname><given-names>A</given-names></name><name><surname>D’Attilio</surname><given-names>L</given-names></name><name><surname>Penas</surname><given-names>F</given-names></name><name><surname>Bongiovanni</surname><given-names>B</given-names></name><name><surname>Massa</surname><given-names>E</given-names></name><name><surname>Cevey</surname><given-names>A</given-names></name><name><surname>Santucci</surname><given-names>N</given-names></name><name><surname>Bottasso</surname><given-names>O</given-names></name><name><surname>Goren</surname><given-names>N</given-names></name><name><surname>Bay</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Studies on the contribution of PPAR Gamma to tuberculosis physiopathology</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>13</volume><elocation-id>1067464</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1067464</pub-id><pub-id pub-id-type="pmid">37187471</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dookie</surname><given-names>N</given-names></name><name><surname>Rambaran</surname><given-names>S</given-names></name><name><surname>Padayatchi</surname><given-names>N</given-names></name><name><surname>Mahomed</surname><given-names>S</given-names></name><name><surname>Naidoo</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evolution of drug resistance in <italic>Mycobacterium tuberculosis</italic>: a review on the molecular determinants of resistance and implications for personalized care</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>73</volume><fpage>1138</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx506</pub-id><pub-id pub-id-type="pmid">29360989</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckhardt</surname><given-names>M</given-names></name><name><surname>Hultquist</surname><given-names>JF</given-names></name><name><surname>Kaake</surname><given-names>RM</given-names></name><name><surname>Hüttenhain</surname><given-names>R</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A systems approach to infectious disease</article-title><source>Nature Reviews. Genetics</source><volume>21</volume><fpage>339</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1038/s41576-020-0212-5</pub-id><pub-id pub-id-type="pmid">32060427</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>CD</given-names></name><name><surname>Lickteig</surname><given-names>AJ</given-names></name><name><surname>Augustine</surname><given-names>LM</given-names></name><name><surname>Ranger-Moore</surname><given-names>J</given-names></name><name><surname>Jackson</surname><given-names>JP</given-names></name><name><surname>Ferguson</surname><given-names>SS</given-names></name><name><surname>Cherrington</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease</article-title><source>Drug Metabolism and Disposition</source><volume>37</volume><fpage>2087</fpage><lpage>2094</lpage><pub-id pub-id-type="doi">10.1124/dmd.109.027466</pub-id><pub-id pub-id-type="pmid">19651758</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gago</surname><given-names>G</given-names></name><name><surname>Diacovich</surname><given-names>L</given-names></name><name><surname>Gramajo</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lipid metabolism and its implication in mycobacteria-host interaction</article-title><source>Current Opinion in Microbiology</source><volume>41</volume><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2017.11.020</pub-id><pub-id pub-id-type="pmid">29190491</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazlehurst</surname><given-names>JM</given-names></name><name><surname>Woods</surname><given-names>C</given-names></name><name><surname>Marjot</surname><given-names>T</given-names></name><name><surname>Cobbold</surname><given-names>JF</given-names></name><name><surname>Tomlinson</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Non-alcoholic fatty liver disease and diabetes</article-title><source>Metabolism</source><volume>65</volume><fpage>1096</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2016.01.001</pub-id><pub-id pub-id-type="pmid">26856933</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>S</given-names></name><name><surname>Kendall</surname><given-names>TJ</given-names></name><name><surname>Pena</surname><given-names>M</given-names></name><name><surname>Yamane</surname><given-names>K</given-names></name><name><surname>Soong</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>L</given-names></name><name><surname>Truman</surname><given-names>R</given-names></name><name><surname>Rambukkana</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>In vivo partial reprogramming by bacteria promotes adult liver organ growth without fibrosis and tumorigenesis</article-title><source>Cell Reports. Medicine</source><volume>3</volume><elocation-id>100820</elocation-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100820</pub-id><pub-id pub-id-type="pmid">36384103</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>AJ</given-names></name><name><surname>Gounder</surname><given-names>L</given-names></name><name><surname>Moosa</surname><given-names>M-YS</given-names></name><name><surname>Drain</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection</article-title><source>BMC Infectious Diseases</source><volume>15</volume><elocation-id>209</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-015-0944-6</pub-id><pub-id pub-id-type="pmid">25943103</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>AA</given-names></name><name><surname>Daginawala</surname><given-names>HF</given-names></name><name><surname>Singh</surname><given-names>L</given-names></name><name><surname>Kashyap</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Current perspective in tuberculosis vaccine development for high TB endemic regions</article-title><source>Tuberculosis</source><volume>98</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2016.03.006</pub-id><pub-id pub-id-type="pmid">27156631</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>N</given-names></name><name><surname>Kalam</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Kedia</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Ahuja</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to <italic>Mycobacterium tuberculosis</italic></article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3062</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16877-3</pub-id><pub-id pub-id-type="pmid">32546788</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen-Cody</surname><given-names>SO</given-names></name><name><surname>Potthoff</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatokines and metabolism: deciphering communication from the liver</article-title><source>Molecular Metabolism</source><volume>44</volume><elocation-id>101138</elocation-id><pub-id pub-id-type="doi">10.1016/j.molmet.2020.101138</pub-id><pub-id pub-id-type="pmid">33285302</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalam</surname><given-names>H</given-names></name><name><surname>Fontana</surname><given-names>MF</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alternate splicing of transcripts shape macrophage response to <italic>Mycobacterium tuberculosis</italic> infection</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006236</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006236</pub-id><pub-id pub-id-type="pmid">28257432</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>NP</given-names></name><name><surname>Moideen</surname><given-names>K</given-names></name><name><surname>Nancy</surname><given-names>A</given-names></name><name><surname>Viswanathan</surname><given-names>V</given-names></name><name><surname>Thiruvengadam</surname><given-names>K</given-names></name><name><surname>Sivakumar</surname><given-names>S</given-names></name><name><surname>Hissar</surname><given-names>S</given-names></name><name><surname>Kornfeld</surname><given-names>H</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Acute phase proteins are baseline predictors of tuberculosis treatment failure</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>731878</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.731878</pub-id><pub-id pub-id-type="pmid">34867953</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerner</surname><given-names>TR</given-names></name><name><surname>Queval</surname><given-names>CJ</given-names></name><name><surname>Lai</surname><given-names>RP</given-names></name><name><surname>Russell</surname><given-names>MR</given-names></name><name><surname>Fearns</surname><given-names>A</given-names></name><name><surname>Greenwood</surname><given-names>DJ</given-names></name><name><surname>Collinson</surname><given-names>L</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Gutierrez</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title><italic>Mycobacterium tuberculosis</italic> cords within lymphatic endothelial cells to evade host immunity</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.136937</pub-id><pub-id pub-id-type="pmid">32369443</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G</given-names></name><name><surname>Sanchis-Gomar</surname><given-names>F</given-names></name><name><surname>Henry</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>COVID-19 and its long-term sequelae: what do we know in 2023?</article-title><source>Polish Archives of Internal Medicine</source><volume>133</volume><elocation-id>16402</elocation-id><pub-id pub-id-type="doi">10.20452/pamw.16402</pub-id><pub-id pub-id-type="pmid">36626183</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Abramovitch</surname><given-names>RB</given-names></name><name><surname>Rohde</surname><given-names>KH</given-names></name><name><surname>Zimmerman</surname><given-names>MD</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Dartois</surname><given-names>V</given-names></name><name><surname>VanderVen</surname><given-names>BC</given-names></name><name><surname>Russell</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Immune activation of the host cell induces drug tolerance in <italic>Mycobacterium tuberculosis</italic> both in vitro and in vivo</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>809</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1084/jem.20151248</pub-id><pub-id pub-id-type="pmid">27114608</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Loddenkemper</surname><given-names>R</given-names></name><name><surname>Lipman</surname><given-names>M</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><source>Clinical Aspects of Adult Tuberculosis</source><publisher-name>Cold Spring Harb Perspect Med</publisher-name><pub-id pub-id-type="doi">10.1101/cshperspect.a017848</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovewell</surname><given-names>RR</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name><name><surname>VanderVen</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chewing the fat: lipid metabolism and homeostasis during <italic>M. tuberculosis</italic> infection</article-title><source>Current Opinion in Microbiology</source><volume>29</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2015.10.002</pub-id><pub-id pub-id-type="pmid">26544033</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>JF</given-names></name><name><surname>Zhu</surname><given-names>MQ</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>NN</given-names></name><name><surname>Liu</surname><given-names>XP</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>RX</given-names></name><name><surname>Xiao</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Wu</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>GDF15 is a major determinant of ketogenic diet-induced weight loss</article-title><source>Cell Metabolism</source><volume>36</volume><fpage>454</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2024.01.004</pub-id><pub-id pub-id-type="pmid">38325339</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luies</surname><given-names>L</given-names></name><name><surname>du Preez</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The echo of pulmonary tuberculosis: mechanisms of clinical symptoms and other disease-induced systemic complications</article-title><source>Clinical Microbiology Reviews</source><volume>33</volume><elocation-id>e00036-20</elocation-id><pub-id pub-id-type="doi">10.1128/CMR.00036-20</pub-id><pub-id pub-id-type="pmid">32611585</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMullan</surname><given-names>GS</given-names></name><name><surname>Lewis</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tuberculosis of the liver, biliary tract, and pancreas</article-title><source>Microbiology Spectrum</source><volume>5</volume><elocation-id>e2016</elocation-id><pub-id pub-id-type="doi">10.1128/microbiolspec.tnmi7-0025-2016</pub-id><pub-id pub-id-type="pmid">28233514</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercado-Gómez</surname><given-names>M</given-names></name><name><surname>Prieto-Fernández</surname><given-names>E</given-names></name><name><surname>Goikoetxea-Usandizaga</surname><given-names>N</given-names></name><name><surname>Vila-Vecilla</surname><given-names>L</given-names></name><name><surname>Azkargorta</surname><given-names>M</given-names></name><name><surname>Bravo</surname><given-names>M</given-names></name><name><surname>Serrano-Maciá</surname><given-names>M</given-names></name><name><surname>Egia-Mendikute</surname><given-names>L</given-names></name><name><surname>Rodríguez-Agudo</surname><given-names>R</given-names></name><name><surname>Lachiondo-Ortega</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Eguileor Giné</surname><given-names>A</given-names></name><name><surname>Gil-Pitarch</surname><given-names>C</given-names></name><name><surname>González-Recio</surname><given-names>I</given-names></name><name><surname>Simón</surname><given-names>J</given-names></name><name><surname>Petrov</surname><given-names>P</given-names></name><name><surname>Jover</surname><given-names>R</given-names></name><name><surname>Martínez-Cruz</surname><given-names>LA</given-names></name><name><surname>Ereño-Orbea</surname><given-names>J</given-names></name><name><surname>Delgado</surname><given-names>TC</given-names></name><name><surname>Elortza</surname><given-names>F</given-names></name><name><surname>Jiménez-Barbero</surname><given-names>J</given-names></name><name><surname>Nogueiras</surname><given-names>R</given-names></name><name><surname>Prevot</surname><given-names>V</given-names></name><name><surname>Palazon</surname><given-names>A</given-names></name><name><surname>Martínez-Chantar</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes</article-title><source>Communications Biology</source><volume>5</volume><elocation-id>827</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-022-03789-9</pub-id><pub-id pub-id-type="pmid">35978143</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Thomas</surname><given-names>DR</given-names></name><name><surname>Wilson</surname><given-names>M-MG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cachexia: pathophysiology and clinical relevance</article-title><source>The American Journal of Clinical Nutrition</source><volume>83</volume><fpage>735</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1093/ajcn/83.4.735</pub-id><pub-id pub-id-type="pmid">16600922</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niazi</surname><given-names>AK</given-names></name><name><surname>Kalra</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Diabetes and tuberculosis: a review of the role of optimal glycemic control</article-title><source>Journal of Diabetes and Metabolic Disorders</source><volume>11</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1186/2251-6581-11-28</pub-id><pub-id pub-id-type="pmid">23497638</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J-H</given-names></name><name><surname>Shim</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>KES</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Understanding metabolic regulation between host and pathogens: new opportunities for the development of improved therapeutic strategies against <italic>Mycobacterium tuberculosis</italic> infection</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>11</volume><elocation-id>635335</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.635335</pub-id><pub-id pub-id-type="pmid">33796480</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyron</surname><given-names>P</given-names></name><name><surname>Vaubourgeix</surname><given-names>J</given-names></name><name><surname>Poquet</surname><given-names>Y</given-names></name><name><surname>Levillain</surname><given-names>F</given-names></name><name><surname>Botanch</surname><given-names>C</given-names></name><name><surname>Bardou</surname><given-names>F</given-names></name><name><surname>Daffé</surname><given-names>M</given-names></name><name><surname>Emile</surname><given-names>J-F</given-names></name><name><surname>Marchou</surname><given-names>B</given-names></name><name><surname>Cardona</surname><given-names>P-J</given-names></name><name><surname>de Chastellier</surname><given-names>C</given-names></name><name><surname>Altare</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for <italic>M. tuberculosis</italic> persistence</article-title><source>PLOS Pathogens</source><volume>4</volume><elocation-id>e1000204</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000204</pub-id><pub-id pub-id-type="pmid">19002241</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinton</surname><given-names>LJ</given-names></name><name><surname>Walkey</surname><given-names>AJ</given-names></name><name><surname>Mizgerd</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Integrative physiology of pneumonia</article-title><source>Physiological Reviews</source><volume>98</volume><fpage>1417</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1152/physrev.00032.2017</pub-id><pub-id pub-id-type="pmid">29767563</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajaram</surname><given-names>MVS</given-names></name><name><surname>Brooks</surname><given-names>MN</given-names></name><name><surname>Morris</surname><given-names>JD</given-names></name><name><surname>Torrelles</surname><given-names>JB</given-names></name><name><surname>Azad</surname><given-names>AK</given-names></name><name><surname>Schlesinger</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title><italic>Mycobacterium tuberculosis</italic> activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses</article-title><source>Journal of Immunology</source><volume>185</volume><fpage>929</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1000866</pub-id><pub-id pub-id-type="pmid">20554962</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rey-Bedon</surname><given-names>C</given-names></name><name><surname>Banik</surname><given-names>P</given-names></name><name><surname>Gokaltun</surname><given-names>A</given-names></name><name><surname>Hofheinz</surname><given-names>O</given-names></name><name><surname>Yarmush</surname><given-names>ML</given-names></name><name><surname>Uygun</surname><given-names>MK</given-names></name><name><surname>Usta</surname><given-names>OB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver</article-title><source>Biomedicine &amp; Pharmacotherapy = Biomedecine &amp; Pharmacotherapie</source><volume>146</volume><elocation-id>112377</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2021.112377</pub-id><pub-id pub-id-type="pmid">35062050</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuels</surname><given-names>AN</given-names></name><name><surname>Wang</surname><given-names>ER</given-names></name><name><surname>Harrison</surname><given-names>GA</given-names></name><name><surname>Valenta</surname><given-names>JC</given-names></name><name><surname>Stallings</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Understanding the contribution of metabolism to <italic>Mycobacterium tuberculosis</italic> drug tolerance</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>12</volume><elocation-id>958555</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.958555</pub-id><pub-id pub-id-type="pmid">36072222</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santucci</surname><given-names>P</given-names></name><name><surname>Greenwood</surname><given-names>DJ</given-names></name><name><surname>Fearns</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Gutierrez</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Intracellular localisation of <italic>Mycobacterium tuberculosis</italic> affects efficacy of the antibiotic pyrazinamide</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3816</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24127-3</pub-id><pub-id pub-id-type="pmid">34155215</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiler</surname><given-names>P</given-names></name><name><surname>Schwendener</surname><given-names>RA</given-names></name><name><surname>Bandermann</surname><given-names>S</given-names></name><name><surname>Brinkmann</surname><given-names>V</given-names></name><name><surname>Grode</surname><given-names>L</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name><name><surname>Aichele</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Limited mycobacterial infection of the liver as a consequence of its microanatomical structure causing restriction of mycobacterial growth to professional phagocytes</article-title><source>Infection and Immunity</source><volume>69</volume><fpage>7922</fpage><lpage>7926</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.12.7922-7926.2001</pub-id><pub-id pub-id-type="pmid">11705978</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seung</surname><given-names>KJ</given-names></name><name><surname>Keshavjee</surname><given-names>S</given-names></name><name><surname>Rich</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>5</volume><elocation-id>a017863</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a017863</pub-id><pub-id pub-id-type="pmid">25918181</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiloh</surname><given-names>MU</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanisms of mycobacterial transmission: how does <italic>Mycobacterium tuberculosis</italic> enter and escape from the human host</article-title><source>Future Microbiology</source><volume>11</volume><fpage>1503</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.2217/fmb-2016-0185</pub-id><pub-id pub-id-type="pmid">27831741</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title><italic>Mycobacterium tuberculosis</italic> infection-driven foamy macrophages and their implications in tuberculosis control as targets for host-directed therapy</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>910</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00910</pub-id><pub-id pub-id-type="pmid">32477367</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotsuka</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Hirai</surname><given-names>S</given-names></name><name><surname>Yamagishi</surname><given-names>F</given-names></name><name><surname>Ueno</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients</article-title><source>In Vivo</source><volume>25</volume><fpage>803</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">21753138</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Toda</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><source>Preparation and Culture of Bone Marrow-Derived Macrophages from Mice for Functional Analysis</source><publisher-name>STAR Protoc</publisher-name><pub-id pub-id-type="doi">10.1016/j.xpro.2020.100246</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turhan</surname><given-names>N</given-names></name><name><surname>Kurt</surname><given-names>M</given-names></name><name><surname>Ozderin</surname><given-names>YO</given-names></name><name><surname>Kurt</surname><given-names>OK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hepatic granulomas: a clinicopathologic analysis of 86 cases</article-title><source>Pathology, Research and Practice</source><volume>207</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2011.03.003</pub-id><pub-id pub-id-type="pmid">21531083</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>So</surname><given-names>K-F</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Organ-organ communication: the liver’s perspective</article-title><source>Theranostics</source><volume>11</volume><fpage>3317</fpage><lpage>3330</lpage><pub-id pub-id-type="doi">10.7150/thno.55795</pub-id><pub-id pub-id-type="pmid">33537089</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The clinical features and prognostic factors of miliary tuberculosis in a high tuberculosis burden area</article-title><source>Annals of Medicine</source><volume>56</volume><elocation-id>2356647</elocation-id><pub-id pub-id-type="doi">10.1080/07853890.2024.2356647</pub-id><pub-id pub-id-type="pmid">38848041</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wölk</surname><given-names>M</given-names></name><name><surname>Fedorova</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The lipid droplet lipidome</article-title><source>FEBS Letters</source><volume>598</volume><fpage>1215</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.14874</pub-id><pub-id pub-id-type="pmid">38604996</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="report"><person-group person-group-type="author"><collab>World Health Organisation</collab></person-group><year iso-8601-date="2023">2023</year><source>Global Tuberculosis Report 2023</source><publisher-name>World Health Organisation</publisher-name></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W-L</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>J-W</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M-X</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Diagnosis and treatment of hepatic tuberculosis: report of five cases and review of literature</article-title><source>International Journal of Clinical and Experimental Medicine</source><volume>6</volume><fpage>845</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">24179582</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>KC</given-names></name><name><surname>Lin</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: evidences in inflammatory diseases and age-related disorders</article-title><source>Journal of Food and Drug Analysis</source><volume>27</volume><fpage>48</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.jfda.2018.11.005</pub-id><pub-id pub-id-type="pmid">30648594</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Important hormones regulating lipid metabolism</article-title><source>Molecules</source><volume>27</volume><elocation-id>7052</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27207052</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>MJ</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hepatocytes: a key cell type for innate immunity</article-title><source>Cellular &amp; Molecular Immunology</source><volume>13</volume><fpage>301</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/cmi.2015.97</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103817.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of the Witwatersrand</institution><country>South Africa</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>This <bold>fundamental</bold> study examines infection of the liver and hepatocytes during tuberculosis infection. The authors <bold>convincingly</bold> demonstrate that aerosol infection of mice and guinea pigs leads to appreciable infection of the liver as well as the lung. A further strength of the study lies in clinical evaluation of the presence of tuberculosis bacteria in human autopsied liver samples from individuals with miliary tuberculosis and the presence of a clear granuloma-like structure, which will prompt further study.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103817.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Authors showed the presence of Mtb in human liver biopsy samples of TB patient and reported that chronic infection of Mtb causes immune-metabolic dysregulation. Authors showed that Mtb replicates in hepatocytes in a lipid rich environment created by up regulating transcription factor PPARγ. Authors also reported that Mtb protects itself from anti-TB drugs by inducing drug metabolising enzymes.</p><p>Strengths:</p><p>It has been shown that Mtb induces storage of triacylglycerol in macrophages by induction of WNT6/ACC2 which helps in its replication and intracellular survival, however, creation of favorable replicative niche in hepatocytes by Mtb is not reported. It is known that Mtb infect macrophages and induces formation of lipid-laden foamy macrophages which eventually causes tissue destruction in TB patient. In a recent article it has been reported that &quot;A terpene nucleoside from <italic>M. tuberculosis</italic> induces lysosomal lipid storage in foamy macrophages&quot; that shows how Mtb manipulates host defense mechanisms for its survival. In this manuscript, authors reported the enhancement of lipid droplets in Mtb infected hepatocytes and convincingly showed that fatty acid synthesis and triacylglycerol formation is important for growth of Mtb in hepatocytes. Authors also showed the molecular mechanism for accumulation of lipid and showed that the transcription factor associated with lipid biogenesis, PPARγ and adipogenic genes were upregulated in Mtb infected cells.</p><p>The comparison of gene expression data between macrophages and hepatocytes by authors is important which indicates that Mtb modulates different pathways in different cell type as in macrophages it is related to immune response whereas, in hepatocytes it is related to metabolic pathways.</p><p>Authors also reported that Mtb residing in hepatocytes showed drug tolerance phenotype due to up regulation of enzymes involved in drug metabolism and showed that cytochrome P450 monooxygenase that metabolize rifampicin and NAT2 gene responsible for N-acetylation of isoniazid were up regulated in Mtb infected cells.</p><p>Weaknesses:</p><p>There are reports of hepatic tuberculosis in pulmonary TB patients especially in immune-compromised patients, therefore finding granuloma in human liver biopsy samples is not surprising.</p><p>Mtb infected hepatic cells showed induced DME and NAT and this could lead to enhanced metabolism of drug by hepatic cells as a result Mtb in side HepG2 cells get exposed to reduced drug concentration and show higher tolerance to drug. Authors mentioned that &quot; hepatocyte resident Mtb may display higher tolerance to rifampicin&quot;. In my opinion higher tolerance to drug is possible only when DME of Mtb inside is up regulated or target is modified. Although, in the end authors mentioned that drug tolerance phenotype can be better attributed to host intrinsic factors rather than Mtb efflux pumps. It may be better if Drug tolerant phenotype section can be rewritten to clarify the facts.</p><p>In the revised manuscript, by immune-staining authors convincingly showed that hepatocytes are a favourable niche for replication of MTb.</p><p>Authors have rewritten the drug tolerant phenotype section which reads better.</p><p>Overall, this paper has new and important information on how MTb establishes a favourable niche for growth in hepatocytes and creates a drug tolerant environment.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103817.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The manuscript by Sarkar et al has demonstrated the infection of liver cells/hepatocytes with Mtb and the significance of liver cells in the replication of Mtb by reprogramming lipid metabolism during tuberculosis. Besides, the present study shows that similar to Mtb infection of macrophages (reviewed in Chen et al., 2024; Toobian et al., 2021), Mtb infects liver cells but with a greater multiplication owing to consumption of enhanced lipid resources mediated by PPARg that could be cleared by its inhibitors. The strength of the study lies in clinical evaluation of the presence of Mtb in human autopsied liver samples from individuals with miliary tuberculosis and presence of a clear granuloma-like structure. The interesting observation is of granuloma-like structure in liver which prompts further investigations in the field.</p><p>The modulation of lipid synthesis during Mtb infection, such as PPARg upregulation, appears generic to different cell types including both liver cells and macrophage cells. It is also known that infection affect PPARγ expression and activity in hepatocytes. It is also known that this can lead to lipid droplet accumulation in the liver and the development of fatty liver disease (as shown for HCV). This study is in similar line for M.tb infection. As liver is the main site for lipid regulation, the availability of lipid resources is greater and higher is the replication rate. In short, the observations from the study confirm the earlier studies with these additional cell types. It is known that higher the lipid content, greater are Lipid Droplet-positive Mtb and higher is the drug resistance (Mekonnen et al., 2021). The DMEs of liver cells add further to the phenotype.</p><p>Comments on revised version:</p><p>The authors noted that even in experiments where mice were infected with lower CFUs, the presence of Mtb colonies could still be detected in the liver. It would be beneficial to include some experimental data related to this in the supplementary information, as it could provide valuable insights for the research field.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103817.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this revised manuscript, the authors explore how Mtb can infect hepatocytes and create a favorable niche associated with upregulation of the transcription factor PPARγ which presumably allows the bacteria to scavenge lipids from lipid droplets in host cells and upregulate drug-metabolizing enzymes to protect against its elimination. In response to the review, the authors have performed some additional immunostaining of hepatocytes, added more detail to figure legends, added experiments somewhat showing improved colocalization and staining, clarified several points and paragraphs, and updated the referenced literature and discussion.</p><p>The current manuscript provides evidence that human miliary TB patients have infection of hepatocytes with Mtb, with evidence that the bacteria survive at least partially through upregulation of PPARγ, which significantly changes the lipid milieu of the cells. There is also an examination of transcriptomics and lipid metabolism in response to Mtb infection, as well as drug tolerance of Mtb inside hepatocytes. The current manuscript is an improvement over the previous one.</p><p>However, although the manuscript is improved, tissue immunophenotyping of the various cells in the liver remains weak and unconvincing. This is truly a missed opportunity and lessens the rigor of the central findings and conclusions. As pointed out by another reviewer, literature has described different fates of Mtb in the liver. Given the tissue available to the authors, carefully dissecting the various cells that the bacteria are in (esp. hepatocytes versus Kupffer cells) is critical. The authors use only 2 generic markers and do not distinguish among cell types within the tissue slices. A review of the literature shows a variety of both human and mouse antibody markers. In fact, a liver atlas based on immunophenotyping has been published. Likewise, the authors comment on liver granulomas, but this is not justified without immunophenotyping.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103817.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sarkar</surname><given-names>Binayak</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Immunology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Jyotsna</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Immunology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Yadav</surname><given-names>Mohit</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Immunology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Priya</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Raman Deep</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Shweta</given-names></name><role specific-use="author">Author</role><aff><institution>CSIR-Institute of Microbial Technology</institution><addr-line><named-content content-type="city">Chandigarh</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Chandramouli</surname><given-names>Aakash</given-names></name><role specific-use="author">Author</role><aff><institution>Indian Institute of Science Education and Research Pune</institution><addr-line><named-content content-type="city">Pune</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Mehdiratta</surname><given-names>Kritee</given-names></name><role specific-use="author">Author</role><aff><institution>CSIR-IGIB</institution><addr-line><named-content content-type="city">india</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Ashwani</given-names></name><role specific-use="author">Author</role><aff><institution>CSIR- Intitute of Microbial Technology</institution><addr-line><named-content content-type="city">Chandigarh</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Kamat</surname><given-names>Siddhesh S</given-names></name><role specific-use="author">Author</role><aff><institution>Indian Institute of Science Education and Research Pune</institution><addr-line><named-content content-type="city">Pune</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Ghorpade</surname><given-names>Devram S</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Immunology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Mohanty</surname><given-names>Debasisa</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Immunology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Gokhale</surname><given-names>Rajesh S</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Immunology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the current reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>Authors showed the presence of Mtb in human liver biopsy samples of TB patient and reported that chronic infection of Mtb causes immune-metabolic dysregulation. Authors showed that Mtb replicates in hepatocytes in a lipid rich environment created by up regulating transcription factor PPARγ. Authors also reported that Mtb protects itself from anti-TB drugs by inducing drug metabolising enzymes.</p><p>Strengths:</p><p>It has been shown that Mtb induces storage of triacylglycerol in macrophages by induction of WNT6/ACC2 which helps in its replication and intracellular survival, however, creation of favorable replicative niche in hepatocytes by Mtb is not reported. It is known that Mtb infect macrophages and induces formation of lipid-laden foamy macrophages which eventually causes tissue destruction in TB patient. In a recent article it has been reported that &quot;A terpene nucleoside from <italic>M. tuberculosis</italic> induces lysosomal lipid storage in foamy macrophages&quot; that shows how Mtb manipulates host defense mechanisms for its survival. In this manuscript, authors reported the enhancement of lipid droplets in Mtb infected hepatocytes and convincingly showed that fatty acid synthesis and triacylglycerol formation is important for growth of Mtb in hepatocytes. Authors also showed the molecular mechanism for accumulation of lipid and showed that the transcription factor associated with lipid biogenesis, PPARγ and adipogenic genes were upregulated in Mtb infected cells.</p><p>The comparison of gene expression data between macrophages and hepatocytes by authors is important which indicates that Mtb modulates different pathways in different cell type as in macrophages it is related to immune response whereas, in hepatocytes it is related to metabolic pathways.</p><p>Authors also reported that Mtb residing in hepatocytes showed drug tolerance phenotype due to up regulation of enzymes involved in drug metabolism and showed that cytochrome P450 monooxygenase that metabolize rifampicin and NAT2 gene responsible for N-acetylation of isoniazid were up regulated in Mtb infected cells.</p><p>Weaknesses:</p><p>There are reports of hepatic tuberculosis in pulmonary TB patients especially in immune-compromised patients, therefore finding granuloma in human liver biopsy samples is not surprising.</p><p>Mtb infected hepatic cells showed induced DME and NAT and this could lead to enhanced metabolism of drug by hepatic cells as a result Mtb in side HepG2 cells get exposed to reduced drug concentration and show higher tolerance to drug. Authors mentioned that &quot; hepatocyte resident Mtb may display higher tolerance to rifampicin&quot;. In my opinion higher tolerance to drug is possible only when DME of Mtb inside is up regulated or target is modified. Although, in the end authors mentioned that drug tolerance phenotype can be better attributed to host intrinsic factors rather than Mtb efflux pumps. It may be better if Drug tolerant phenotype section can be rewritten to clarify the facts.</p><p>In the revised manuscript, by immune-staining authors convincingly showed that hepatocytes are a favourable niche for replication of MTb.</p><p>Authors have rewritten the drug tolerant phenotype section which reads better.</p><p>Overall, this paper has new and important information on how MTb establishes a favourable niche for growth in hepatocytes and creates a drug tolerant environment.</p></disp-quote><p>We thank the reviewer for the through and insightful review.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review)</bold>:</p><p>The manuscript by Sarkar et al has demonstrated the infection of liver cells/hepatocytes with Mtb and the significance of liver cells in the replication of Mtb by reprogramming lipid metabolism during tuberculosis. Besides, the present study shows that similar to Mtb infection of macrophages (reviewed in Chen et al., 2024; Toobian et al., 2021), Mtb infects liver cells but with a greater multiplication owing to consumption of enhanced lipid resources mediated by PPARg that could be cleared by its inhibitors. The strength of the study lies in clinical evaluation of the presence of Mtb in human autopsied liver samples from individuals with miliary tuberculosis and presence of a clear granuloma-like structure. The interesting observation is of granuloma-like structure in liver which prompts further investigations in the field.</p><p>The modulation of lipid synthesis during Mtb infection, such as PPARg upregulation, appears generic to different cell types including both liver cells and macrophage cells. It is also known that infection affect PPARγ expression and activity in hepatocytes. It is also known that this can lead to lipid droplet accumulation in the liver and the development of fatty liver disease (as shown for HCV). This study is in similar line for M.tb infection. As liver is the main site for lipid regulation, the availability of lipid resources is greater and higher is the replication rate. In short, the observations from the study confirm the earlier studies with these additional cell types. It is known that higher the lipid content, greater are Lipid Droplet-positive Mtb and higher is the drug resistance (Mekonnen et al., 2021). The DMEs of liver cells add further to the phenotype.</p><p>Comments on revised version:</p><p>The authors noted that even in experiments where mice were infected with lower CFUs, the presence of Mtb colonies could still be detected in the liver. It would be beneficial to include some experimental data related to this in the supplementary information, as it could provide valuable insights for the research field.</p></disp-quote><p>We thank the reviewer for the in depth evaluation of our manuscript and as suggested we will include the data where Mtb was detected in the liver at low CFUs</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>In this revised manuscript, the authors explore how Mtb can infect hepatocytes and create a favorable niche associated with upregulation of the transcription factor PPARγ which presumably allows the bacteria to scavenge lipids from lipid droplets in host cells and upregulate drug-metabolizing enzymes to protect against its elimination. In response to the review, the authors have performed some additional immunostaining of hepatocytes, added more detail to figure legends, added experiments somewhat showing improved colocalization and staining, clarified several points and paragraphs, and updated the referenced literature and discussion.</p><p>The current manuscript provides evidence that human miliary TB patients have infection of hepatocytes with Mtb, with evidence that the bacteria survive at least partially through upregulation of PPARγ, which significantly changes the lipid milieu of the cells. There is also an examination of transcriptomics and lipid metabolism in response to Mtb infection, as well as drug tolerance of Mtb inside hepatocytes. The current manuscript is an improvement over the previous one.</p><p>However, although the manuscript is improved, tissue immunophenotyping of the various cells in the liver remains weak and unconvincing. This is truly a missed opportunity and lessens the rigor of the central findings and conclusions. As pointed out by another reviewer, literature has described different fates of Mtb in the liver. Given the tissue available to the authors, carefully dissecting the various cells that the bacteria are in (esp. hepatocytes versus Kupffer cells) is critical. The authors use only 2 generic markers and do not distinguish among cell types within the tissue slices. A review of the literature shows a variety of both human and mouse antibody markers. In fact, a liver atlas based on immunophenotyping has been published. Likewise, the authors comment on liver granulomas, but this is not justified without immunophenotyping.</p></disp-quote><p>We would like to thank the reviewer for the in-depth and detailed suggestions. We would like to clarify that the primary aim of our study was to determine the localization of Mtb within hepatocytes and the downstream biological consequences. To this end, we employed two well-established and widely validated markers (ASPGR 1 and albumin) that are consistently used to identify hepatocytes in both human and murine liver tissue. While we acknowledge the broader potential of comprehensive immunophenotyping, our focused approach was designed to specifically address the question of hepatocyte involvement, which the selected markers effectively support, which was further reiterated by the Reviewer 1.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>In my opinion this paper contains important information and no further information is required for this manuscript.</p></disp-quote><p>We thank the reviewer for the insightful comments</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>The authors noted that even in experiments where mice were infected with lower CFUs, the presence of Mtb colonies could still be detected in the liver. It would be beneficial to include some experimental data related to this in the supplementary information, as it could provide valuable insights for the research field.</p></disp-quote><p>As suggested, we will include the data with the low CFUs in the updated manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>• Line 340, the fact that PPARγ inhibition decreases bacterial load should not be surprising, as the authors cite several papers where this is already shown.</p><p>• Line 379, the increased tolerance of Mtb to drugs in hepatocytes is only significant at the lower 2 concentrations, not at 5 ug/mL.</p><p>• Fig S4F-H, the y axis is inappropriately not set to zero on the lower limit.</p><p>• Fig S9B, the Y-axis states &quot;relative&quot; CFU, but there is no indication what the bars are normalized to, and the numbers are much more typical of standard CFU values. Was the &quot;Relative&quot; part left in by mistake?</p><p>• Double check the ending of the figure legend for Figure S10 and S11.</p><p>• Line 352, phenomenom [sic] is misspelled.</p><p>• On re-read, several sentences throughout this manuscript need improvement regarding structure and grammar. I suggest careful editorial review.</p></disp-quote><p>We thank the reviewer for pointing out the issues and these will be carefully modified in the next version.</p><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>The authors showed the presence of Mtb in human liver biopsy samples of TB patients and reported that chronic infection of Mtb causes immune-metabolic dysregulation. Authors showed that Mtb replicates in hepatocytes in a lipid rich environment created by up regulating transcription factor PPARγ. Authors also reported that Mtb protects itself from anti-TB drugs by inducing drug metabolising enzymes.</p><p>Strengths:</p><p>It has been shown that Mtb induces storage of triacylglycerol in macrophages by induction of WNT6/ACC2 which helps in its replication and intracellular survival, however, creation of favorable replicative niche in hepatocytes by Mtb is not reported. It is known that Mtb infects macrophages and induces formation of lipid-laden foamy macrophages which eventually causes tissue destruction in TB patients. In a recent article it has been reported that &quot;A terpene nucleoside from <italic>M. tuberculosis</italic> induces lysosomal lipid storage in foamy macrophages&quot; that shows how Mtb manipulates host defense mechanisms for its survival. In this manuscript, authors reported the enhancement of lipid droplets in Mtb infected hepatocytes and convincingly showed that fatty acid synthesis and triacylglycerol formation is important for growth of Mtb in hepatocytes. The authors also showed the molecular mechanism for accumulation of lipid and showed that the transcription factor associated with lipid biogenesis, PPARγ and adipogenic genes were upregulated in Mtb infected cells.</p><p>The comparison of gene expression data between macrophages and hepatocytes by authors is important which indicates that Mtb modulates different pathways in different cell type as in macrophages it is related to immune response whereas, in hepatocytes it is related to metabolic pathways.</p><p>Authors also reported that Mtb residing in hepatocytes showed drug tolerance phenotype due to up regulation of enzymes involved in drug metabolism and showed that cytochrome P450 monooxygenase that metabolize rifampicin and NAT2 gene responsible for N-acetylation of isoniazid were up regulated in Mtb infected cells.</p></disp-quote><p>We thank the reviewer for the positive feedback and for highlighting the strengths of our study.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>There are reports of hepatic tuberculosis in pulmonary TB patients especially in immune-compromised patients, therefore finding granuloma in human liver biopsy samples is not surprising.</p><p>Mtb infected hepatic cells showed induced DME and NAT and this could lead to enhanced metabolism of drug by hepatic cells as a result Mtb in side HepG2 cells get exposed to reduced drug concentration and show higher tolerance to drug. The authors mentioned that &quot; hepatocyte resident Mtb may display higher tolerance to rifampicin&quot;. In my opinion higher tolerance to drugs is possible only when DME of Mtb inside is up regulated or the target is modified. Although, in the end authors mentioned that drug tolerance phenotype can be better attributed to host intrinsic factors rather than Mtb efflux pumps. It may be better if the Drug tolerant phenotype section can be rewritten to clarify the facts.</p></disp-quote><p>We agree that several case studies regarding liver infection in pulmonary TB patients have been reported in the literature, however this report is the first comprehensive study that establishes hepatocytes to be a favourable niche for Mtb survival and growth.</p><p>Drug tolerance is a phenomenon that is exhibited by the bacteria and during hostpathogen interactions, can be influenced by both intrinsic (bacterial) and extrinsic (host-mediated) factors. Multiple examples of tolerance being attributed to host driven factors can be found in literature (PMID 32546788, PMID: 28659799, PMID: 32846197). Our studies demonstrate that Mtb infected hepatocytes create a drug tolerant environment by modulating the expression of Drug modifying enzymes (DMEs) in the hepatocytes.</p><p>As suggested by the reviewer we will rewrite the drug tolerant phenotype section.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>The manuscript by Sarkar et al has demonstrated the infection of liver cells/hepatocytes with Mtb and the significance of liver cells in the replication of Mtb by reprogramming lipid metabolism during tuberculosis. Besides, the present study shows that similar to Mtb infection of macrophages (reviewed in Chen et al., 2024; Toobian et al., 2021), Mtb infects liver cells but with a greater multiplication owing to consumption of enhanced lipid resources mediated by PPARg that could be cleared by its inhibitors. The strength of the study lies in the clinical evaluation of the presence of Mtb in human autopsied liver samples from individuals with miliary tuberculosis and the presence of a clear granuloma-like structure. The interesting observation is of granuloma-like structure in liver which prompts further investigations in the field.</p><p>The modulation of lipid synthesis during Mtb infection, such as PPARg upregulation, appears generic to different cell types including both liver cells and macrophage cells. It is also known that infection affect PPARγ expression and activity in hepatocytes. It is also known that this can lead to lipid droplet accumulation in the liver and the development of fatty liver disease (as shown for HCV). This study is in a similar line for M.tb infection. As the liver is the main site for lipid regulation, the availability of lipid resources is greater and higher is the replication rate. In short, the observations from the study confirm the earlier studies with these additional cell types. It is known that higher the lipid content, the greater are Lipid Droplet-positive Mtb and higher is the drug resistance (Mekonnen et al., 2021). The DMEs of liver cells add further to the phenotype.</p></disp-quote><p>We thank the reviewer for emphasizing on the strengths of our study and how it can lead to further investigations in the field.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>This manuscript by Sarkar et al. examines the infection of the liver and hepatocytes during <italic>M. tuberculosis</italic> infection. They demonstrate that aerosol infection of mice and guinea pigs leads to appreciable infection of the liver as well as the lung. Transcriptomic analysis of HepG2 cells showed differential regulation of metabolic pathways including fatty acid metabolic processing. Hepatocyte infection is assisted by fatty acid synthesis in the liver and inhibiting this caused reduced Mtb growth. The nuclear receptor PPARg was upregulated by Mtb infection and inhibition or agonism of its activity caused a reduction or increase in Mtb growth, respectively, supporting data published elsewhere about the role of PPARg in lung macrophage Mtb infection. Finally, the authors show that Mtb infection of hepatocytes can cause upregulation of enzymes that metabolize antibiotics, resulting in increased tolerance of these drugs by Mtb in the liver.</p><p>Overall, this is an interesting paper on an area of TB research where we lack understanding. However, some additions to the experiments and figures are needed to improve the rigor of the paper and further support the findings. Most importantly, although the authors show that Mtb can infect hepatocytes in vitro, they fail to describe how bacteria get from the lungs to the liver in an aerosolized infection. They also claim that &quot;PPARg activation resulting in lipid droplets formation by Mtb might be a mechanism of prolonging survival within hepatocytes&quot; but do not show a direct interaction between PPARg activation and lipid droplet formation and lipid metabolism, only that PPARg promotes Mtb growth. Thus, the correlations with PPARg appear to be there but causation, implied in the abstract and discussion, is not proven.</p><p>The human photomicrographs are important and overall, well done (lung and liver from the same individuals is excellent). However, in lines 120-121, the authors comment on the absence of studies on the precise involvement of different cells in the liver. In this study there is no attempt to immunophenotype the nature of the cells harboring Mtb in these samples (esp. hepatocytes). Proving that hepatocytes specifically harbor the bacteria in these human samples would add significant rigor to the conclusions made.</p></disp-quote><p>We thank the reviewer for nicely summarizing our manuscript.</p><p>Our study establishes the involvement of liver and hepatocytes in pulmonary TB infection in mice. Understanding the mechanism of bacterial dissemination from the lung to the liver in aerosol infections demands a detailed separate study.</p><p>Figure 6E and 6F shows how PPARγ agonist and antagonist modulate (increase and decrease respectively) bacterial growth in hepatocytes (further supported by the CFU data in Supplementary Figure 9B). Again, the number of lipid droplets in hepatocytes increase and decrease with the treatment of PPARγ agonist and antagonist respectively as shown in Figure 6G and 6H. Collectively, these studies provide strong evidence that PPARγ activation leads to more lipid droplets that support better Mtb growth.</p><p>We thank the reviewer for finding our human photomicrographs convincing. In the manuscript, we provide evidence for the direct involvement of the hepatocytes (and liver) in Mtb infection. We have performed detailed immunophenotyping of hepatocyte cells in the mice model with ASPGR1 (asialoglycoprotein receptor 1) and in the revised version of record, we have further stained the infected hepatocytes with anti-albumin antibody.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>In my opinion drug tolerant phenotype section should be rewritten for better clarification. The manuscript contains important information about hepatic tuberculosis which are not reported yet.</p></disp-quote><p>We have rewritten the drug tolerant phenotype section for better clarity.</p><p>We appreciate the reviewer’s comments regarding important information about hepatic tuberculosis</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>The following are some observations and comments on the manuscript.</p><p>(1) The study delves into the mechanisms related to hepatic TB/miliary TB; however, the introduction and discussion only describe and discuss the data in the context of pulmonary TB giving a sense that the mandate of the MS is the exploration of the role of liver cells in pulmonary TB. There appears a gap in the connection of findings from the Miliary TB to the pulmonary TB. A discussion of the conversion of pulmonary TB to extrapulmonary /hepatic TB in the light of the findings may be helpful.</p></disp-quote><p>We have modified the discussion section to include possible mechanisms that convert pulmonary TB to hepatic TB in the light of findings. Briefly, Pulmonary tuberculosis (TB) can lead to miliary TB probably through hematogenous dissemination, where Mtb spreads from the infected lungs into blood vessels either from a primary lung focus, reactivated TB or caseous necrosis. Once in blood vessels, the bacteria seed multiple organs, forming tiny granulomas, characteristic of miliary TB. The liver involvement could be either through direct hematogenous spread or extrusion from nearby infected lymph nodes, leading to hepatic TB, which presents with granulomas and liver dysfunction. This spread underscores the severity of untreated pulmonary TB and the need for early intervention. Our in vivo infection data clearly shows that pulmonary infection of Mtb in mice and guinea pigs can steadily leads to significant infection of the liver and metabolic abnormalities in the liver. The study further highlights the need for systemic studies to better understand the route and mode of dissemination from lungs to liver for better pathophysiological understanding of the disease and creating new therapeutic targets.</p><disp-quote content-type="editor-comment"><p>(2) The authors show the presence of Mtb in the liver autopsies of miliary tuberculosis patients. It is well known that Mtb disseminates during the late stages to several organs and liver is a major site (Sharma et al. 2005; 10.1016/S1473-3099(05)70163-8). Other clinical observations also point to the fact that although Mtb infects liver cells, it is cleared (Thandi et al., 2018, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.200.Supp.173.20">https://doi.org/10.4049/jimmunol.200.Supp.173.20</ext-link>). As the samples are from miliary TB, it is expected that the bacterial load must have been very high before spreading to blood. It is known that once in blood, M.tb is expected to spread to various organs, especially highly vascular ones. Were any other tissues (especially with high vasculature) stained and verified? If yes, add to the supplementary data or discuss.</p></disp-quote><p>Other tissues were not collected and stained during this study. Studies are currently underway to understand whether other vasculated organs also harbour Mtb or not. Besides several studies have shown that Mtb can infect a wide range of organs like brain, kidney, bone marrow, etc (PMID: 33142108, PMID: 28046053, PMID: 34269789) during miliary conditions.</p><disp-quote content-type="editor-comment"><p>(3) It is not evident from this paper if hepatic infiltration occurs in pulmonary TB patients? It may therefore be important to discuss the status of liver infections in the primary pulmonary infection.</p></disp-quote><p>Based on the available data from human biopsied liver samples, there is an indication of liver involvement in systemic tuberculosis (TB). However, to gain a more comprehensive understanding of hepatic infiltration in pulmonary TB patients, it is essential to conduct well-organized clinical studies. These studies should specifically target pulmonary TB patients and explore the extent and nature of liver involvement in these individuals (discussion). As suggested by the reviewer it is in the discussion</p><disp-quote content-type="editor-comment"><p>(4) Similarly, in the mice model, M.tb was shown to localize to liver when aerosolic infection was given. Were any other tissues, such as kidney, bone marrow etc, checked? Is it because of the high dose of M.tb against the standard challenge dose of 50-100 CFU? Further, since the study in the mouse model is to mimic a miliary tuberculosis of liver, did the dissemination occur via bloodstream and if mycobacteremia could be observed in infected mice.</p></disp-quote><p>Currently studies are underway to understand the involvement of other organs like kidney, brain, bone marrow, in aerosol infection mice model and how dissemination occurs in those distant organs.</p><p>The focus of the current study was to understand the role of liver in systemic tuberculosis with emphasis on hepatocytes as a key cell type to be infected. We have also conducted the experiments with lower CFUs and could detect the presence of Mtb colonies in liver, so we do not think that the infection of liver is dependent on the dose of infection.</p><disp-quote content-type="editor-comment"><p>(5) There are studies in mouse model which infer that liver carried the lowest bacterial burden, was cleared the fastest, and it is established that as compared to sites persistently seeded by <italic>M. tuberculosis</italic>, in the liver the bacteria rarely infect cell types other than professional phagocytes. As the observations in this study are contrasting, the discussion section should include a critical comparative analysis to justify why in the conditions used in the study, the hepatocytes and not Kupffer cells are infected. Other than the morphological description to indicate M.tb infection of hepatocytes in the liver section (fig 1E), it will be good to show localization of M.tb specifically to hepatocytes by using hepatocyte specific marker. Unlike as reported, why was a clearance of M.tb not observed even after 10 weeks (figure 2B).</p></disp-quote><p>While some studies show that Mtb from the liver is cleared fast but there are several other studies that report Liver harbours Mtb even after 10 weeks postinfection (PMID: 22359543, PMID: 21533158, PMID: 29242198). We have consistently observed Mtb infection of liver post week 10 in our infection model.</p><p>We have performed detailed immunophenotyping of hepatocyte cells in the mice model with ASPGR1 (asialoglycoprotein receptor 1) and in the revised version of record, we have further stained the isolated hepatocytes with anti-albumin antibody (albumin is a robust marker of hepatocyte identity) and have showed the presence of Mtb in it. The data has been included in the revised manuscript (Fig 2J)</p><disp-quote content-type="editor-comment"><p>(6) While the result section mentions that &quot;individuals with miliary tuberculosis' (line 107), the legend of Figure 1 writes 'Presence of Mtb in human pulmonary tuberculosis patients'. This is confusing. Clarify</p></disp-quote><p>We thank the reviewer for pointing it out, we have changed the figure legends to miliary tuberculosis as most of the liver biopsy samples were obtained from military tuberculosis patients.</p><disp-quote content-type="editor-comment"><p>(7) Supplementary Figure 2D: Corresponding control panel (uninfected) should be added, which will also verify the specificity of Ag85b. As it is known that Ag85B is secreted out from the bacteria and hence the detected signals may not confirm that Mtb is in hepatocytes. Ag85B per bacterium decreases by almost 10,000-fold at later stages of infection because of secretion (Ernst JD, Cornelius A, et al 2019 mBio). In Supl figure 2D, Ag85b signal seems to be present everywhere inside the cells. Hence, it is important that the control panel be added.</p></disp-quote><p>We have included a control image below which shows no staining of Ag85B in the uninfected sample.While we acknowledge with the reviewer’s comment, but Ag85B has been consistently used as a marker for Mtb presence in multiple studies. Nargan et al., uses Ag85B based staining to characterize infection both pulmonary and EPTB samples (PMID: 38880068). Jain et al., uses Ag85B to characterize Mtb infection of Mesenchymal stem cell in lung biopsy samples of pulmonary TB patients (PMID: 32546788)</p><fig id="sa4fig1" position="float"><label>Author response image 1.</label><caption><title>Ag85B staining in uninfected mice shows no signals.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-sa4-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(8) The kinetics experiments in Figure 3D-3G should have used time laps microscopy of a few of the infected cells or it should be represented in CFU. If we consider the doubling time of H37Rv is about 22h to 24h, the data showing that MFI increases dramatically from 5 HPI to 120 HPI, gives an impression that the bacterial number inside the cells increased more than its doubling time.</p></disp-quote><p>We have added the modified plot. As suggested, the CFU of Mtb within HepG2, PHCs, THP-1, RAW 264.7 and BMDMs have been included in the revised version (Supplementary Figure 4 D-H)</p><disp-quote content-type="editor-comment"><p>(9) What is the effect of C45 and T863 on Mtb growth invitro? The effect of C45 and T863 on Mtb growth invitro should be shown to be ruled out. The representative image in Figure 5F is DMSO or C45 treated cells panel? Please specify it.</p></disp-quote><p>As per the reviewer’s suggestion we have seen the effect of C45 (30 µM) and T863 (25 µM) on Mtb growth in vitro and did not find any difference in the growth kinetics. The representative image in Figure 5F is DMSO treated cells.</p><fig id="sa4fig2" position="float"><label>Author response image 2.</label><caption><title>Growth kinetics of Mtb in 7H9 medium with DMSO, C75 and T863.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-sa4-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(10) Supplementary Figure 6B: Correct the Y-axis label from mRNA levels to Fold change (normalised to control). Please do similar changes wherever required.</p></disp-quote><p>We have made the necessary changes as per the suggestion of the reviewer.</p><disp-quote content-type="editor-comment"><p>(11) Figure 7B and 7C: How was the normalization performed? Is the data normalized to the number of bacteria that entered the specific cell type or was normalized at 48hrs with respect to DMSO? DMSO alone data should be shown.</p></disp-quote><p>In the drug tolerance assays, we have calculated the ratio of the bacterial burden in hepatocytes treated with drugs compared to hepatocytes treated with DMSO. The infection was given for 48 hours post which the infected cells were treated with the mentioned concentrations of isoniazid and rifampicin for 24 hours. CFU enumeration was conducted after this 24 hour. Figure 7A gives a schematic of the experimental set up.</p><p>% Tolerant Bacterial population = [A/B X 100] % where A is the CFU of Mtb from infected hepatocytes treated with drug and B is the CFU of Mtb infected cells treated with DMSO.Thus the effect of MOI is negated.</p><p>To provide further credence to the CFU data, we have analysed these studies using microscopic studies as well, where no cell death was observed under the conditions. Mouse BMDMs were as a macrophage control. We have calculated the % tolerance as ratio by measuring the mean fluorescent intensity of GFP-Mtb per hepatocyte treated with drug to MFI of GFP-Mtb per hepatocyte treated with DMSO (control). More than 20 fields, each consisting of more than 4 infected cells have been used for analysis providing additional evidence of less killing of Mtb in hepatocytes compared to BMDMs with anti-TB drugs. All these details are included in the manuscript.</p><disp-quote content-type="editor-comment"><p>(12) While authors have shown the changes in mRNA levels of CYP3A4, CYP3A43, NAT2, the protein or activities of some of these should be measured to verify the effect.</p></disp-quote><p>Currently studies are underway to understand the activities of the key proteins involved in isoniazid and rifampicin metabolism and will be published as a separate manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>Additional comments are:</p><p>• Figure 2D, the 20X and 40X magnifications do not look appreciably different in size. Please double-check that the correct images were used.</p></disp-quote><p>We thank the reviewer for pointing it out, we havecorrected it in the revised version.</p><disp-quote content-type="editor-comment"><p>• Lines 162-164: The authors state almost 100% purity. However, the contour plot in 2F appears to show 2 cell populations. Figure 2G is missing a legend of which colors correspond to which staining (and again there appears to be highly variable staining).</p></disp-quote><p>We agree with the reviewer that there are two contours observed in Figure 2F. Although both the contours are positive for ASPGR1 protein, but the level of expression of the ASPGR1 protein is variable. The corresponding confocal image (Nucleus stained by DAPI and ASPGR1 stained with ASPGR1 antibody with Alexa fluor 555 conjugated secondary antibody) also indicates a variable staining of isolated primary hepatocytes, where some cells give a stronger intensity signal than the other cells, further visually confirming our statement. Moreover, several studies show differential expression of ASPGR1 protein in hepatocyte like cells (PMID: 27143754)</p><p>To further clarify and be more specific with respect to the identity of the hepatocytes, we have stained primary hepatocytes from infected mouse livers with Albumin antibody (a stable marker for hepatocytes) and Ag85B (2J)</p><disp-quote content-type="editor-comment"><p>Multiple figures throughout the manuscript, including this one, would benefit from the use of arrows to depict what is described in the legend and text more clearly, and the use of higher power insets to better define cell architecture. Finally, some images appear blurry to the eye. Improvements are needed throughout.</p></disp-quote><p>As per the suggestion, we have modified the figures and figure legends for better clarity.</p><disp-quote content-type="editor-comment"><p>• Lines 153-155. Albumin, AST and GGT appear to be significantly up at week 8, contradicting the statement that there is no change until week 10.</p></disp-quote><p>We thank the reviewer for poiting it out and have made suitable changes in the write up</p><disp-quote content-type="editor-comment"><p>• Lines 203-205: The authors state earlier that bacteria survive in macrophage phagosomes. Do the authors know the niche for bacteria in hepatocytes that enable them to continue to grow? Transcriptome data from HepG2 cells suggest perhaps a phagosomal pathway?</p></disp-quote><p>We thank the reviewer for this insightful question. As rightly pointed out by the reviewer, transcription data indeed suggests changes in several important pathways like macroautophagy, golgi vesicular transport and vacuolar transport, which can affect the subcellular localisation of Mtb within hepatocytes. High resolution microscopic studies with respect to the subcellular localisation of labelled Mtb within Primary hepatocytes, HepG2 and THP-1 has been conducted and the % colocalization within different intra-cellular compartments have been measured. The image of colocalization of labelled Mtb within PHCs is shown below along with the % colocalization within various compartments in PHCs, HepG2 and THP-1 is added.</p><fig id="sa4fig3" position="float"><label>Author response image 3.</label><caption><title>Colocalisation of Mtb-GFP with various intra-cellular markers within PHCs.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-sa4-fig3-v1.tif"/></fig><fig id="sa4fig4" position="float"><label>Author response image 4.</label><caption><title>Percentage Colocalisation of Mtb-GFP with various intra-cellular markers within PHCs, HepG2 and THP-1.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-sa4-fig4-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>• Validation of some critical genes found in the HepG2 cells should be done by qRTPCR in primary hepatocytes.</p></disp-quote><p>qRT-PCR analysis of some of the key genes in HepG2 have been validated in primary hepatocytes at 24 hours post infection. Majority of the genes show a similar trend.</p><fig id="sa4fig5" position="float"><label>Author response image 5.</label><caption><title>Gene expression analysis of the mentioned genes in Mtb infected PHCs as compared to the uninfected control.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103817-sa4-fig5-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>• Lines 259-260: The authors state a high degree of co-localization. The photomicrograph of a single cell in Fig. 5D is not convincing. I'm not even sure that they are really in the same subcellular compartment. Co-localization stated in Fig. S8B is also not convincing as shown.</p></disp-quote><p>The image currently shown in figure 3D is a maximum intensity projection image of multiple z-stacks encompassing the entire cell.</p><p>We agree with the reviewer with respect to figure Fig S8B and will modify the text and the figure legend accordingly.</p><disp-quote content-type="editor-comment"><p>Copywriting edits:</p><p>• It is difficult to see individual gene names in Figures 4D and 4E. A higher resolution or larger font would be appreciated for the reader.</p></disp-quote><p>An excel file with the top differentially regulated genes at both 0 hours post infection and 48 hours post infection has been added.</p><disp-quote content-type="editor-comment"><p>• Figure 5A has a shadow on the top right image.</p></disp-quote><p>We have changed the image in the revised manuscript</p><disp-quote content-type="editor-comment"><p>• Figure 5E is difficult to read the labels on the axes; it would be better in general to make the labels separately instead of relying on the graphing software, since these labels can get stretched when the size of the graph is modified.</p></disp-quote><p>We agree with the reviewer and have made necessary changes.</p><disp-quote content-type="editor-comment"><p>• Line 163: should be &quot;percent&quot; and not &quot;perfect.&quot;</p></disp-quote><p>We thank the reviewer for pointing it out and have corrected it</p><disp-quote content-type="editor-comment"><p>• Line 190: is missing a period at the end of the sentence &quot;...for further experiments&quot;</p></disp-quote><p>We thank the reviewer for pointing it out and have corrected it</p><disp-quote content-type="editor-comment"><p>• Line 332: should be &quot;hepatocytes&quot; instead of &quot;hepatoctyte&quot; [sic]</p></disp-quote><p>We thank the reviewer for pointing it out and have corrected it</p></body></sub-article></article>